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This series of studies was carried in order to develop and validate the Alzheimer’s 
Questionnaire (AQ). The underlying rationale for the creation of the AQ was to provide 
clinicians with a brief and easy-to-use informant-based assessment of symptoms associated 
with Alzheimer’s disease (AD). Initial studies of the AQ found that it has both high 
sensitivity and high specificity for differentiating individuals with AD and its prodrome, 
amnestic mild cognitive impairment (MCI). The AQ’s accuracy in identifying MCI was 
explored further in an additional study which sought to determine which items on the AQ 
were best predicted the presence of MCI. Four items were strongly associated with MCI 
which were: repetition of statements and/or questions [OR = 13.20 (3.02, 57.66)]; trouble 
knowing the day, date, month, year, and time [OR = 17.97 (2.63, 122.77)]; difficulty 
managing finances [OR = 11.60 (2.10, 63.99)]; and decreased sense of direction [OR = 5.84 
(1.09, 31.30)]. Concurrent validity was established through another study which found that 
the AQ correlated moderately with the MMSE (r = -0.56) and MoCA (r = -0.46) while a 
strong correlation (r = 0.79) was found with the Clinical Dementia Rating Sum of Boxes 
(CDR-SOB). Additional work found that the AQ correlated well with formal 
neuropsychological measures of episodic memory and executive function. Longitudinal 
analyses found that was AQ was a significant predictor of clinically meaningful decline as 
measured by the changes in CDR Global Score (OR = 1.20, 95% CI: 1.09, 1.32; p<0.001). In 
addition, AQ identified clinically meaningful change among MCI cases at a greater rate 
(24%) than the MMSE (17%). This series of studies demonstrates that the AQ is an accurate 




List of Contents 
 
 




1.1 Overview of AD 
 
1.2 Overview of MCI 
 
1.3 Epidemiology of MCI 
 
1.4 Evolution of MCI 
 
1.5 Assessment of Cognitive Impairment 
 
1.6 Informant-Based Assessment 
 
1.7 Overview of the AQ 
 
2. Pilot Study 
 
3. Validation Study 
 
4. Item Analysis Study 
 
5. Concurrent Validity 
 
6. Neuropsychological Correlates 
 














List of Tables and Figures 
 
 
Table 1. Pilot Study Diagnostic Accuracy Results for the AQ.  
 
Table 2. Pilot Study Diagnostic Accuracy Results for the AQ Items Without Weightings. 
 
Table 3.  Validation Study Diagnostic Accuracy Results of the AQ in MCI and AD. 
 
Table 4.  Analysis of Individual AQ Items as Predictors of MCI. 
 
Table 5: Diagnostic Accuracy Comparison of AQ, CDR-SOB, MMSE, and MoCA.  
 
Table 6. Correlation Values for Neuropsychological Tests with the AQ. 
 
Table 7. Additional Diagnostic Accuracy of Select Cognitive Tests with AQ in MCI 
Cases.  
 
Figure 1. AQ Performance for CDR Global Score Groupings. 
 
Appendix 1. The Alzheimer’s Questionnaire. 
 
Appendix 2. Sabbagh MN, Malek-Ahmadi M, Kataria R, Belden CM, Connor DJ, Pearson 
C, Jacobson S, Davis K, Yaari R, Singh U. The Alzheimer’s Questionnaire: A proof of 
concept study for a new informant-based dementia assessment.  Journal of Alzheimer’s 
Disease 2010;22(3):1015-1021. 
 
Appendix 3. Malek-Ahmadi M, Davis K, Belden CM, Laizure B, Jacobson SA, Yaari R, 
Singh U, Sabbagh MN.  Validation and diagnostic accuracy of the Alzheimer’s Questionnaire 
(AQ). Age and Ageing 2012;41(3):396-399. 
 
Appendix 4. Malek-Ahmadi M, Davis K, Belden CM, Jacobson SA, Sabbagh MN. 
Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment. 
BMC Geriatrics 2012;12:3. 
 
Appendix 5. Malek-Ahmadi M, Davis K, Belden C, Sabbagh MN. Comparative analysis of 
the Alzheimer’s Questionnaire (AQ) with the CDR Sum of Boxes, MoCA, and MMSE. 
Alzheimer’s Disease and Associated Disorders 2014;28(3):296-298. 
 
Appendix 6. Budolfson K, Malek-Ahmadi M, Belden C, Powell J, Davis K, Jacobson SA, 
Sabbagh MN. Neuropsychological correlates of the Alzheimer’s Questionnaire (AQ). Journal 
of Alzheimer’s Disease 2015;46(2):389-397. 
 
Appendix 7. Malek-Ahmadi M, Chen K, Davis K, Belden CM, Powell J, Jacobson SA, 
Sabbagh MN. Sensitivity to change and prediction of global change for the Alzheimer’s 






I would like to thank Drs. Catherine Loveday and Trudi Edginton for their guidance in the 
drafting of this thesis and for allowing me the opportunity to earn a PhD from the University 
of Westminster. 
 
I would also like to thank the many mentors who have shaped my career: Dr. Alfred 
Kaszniak, Dr. Keith Burton, Dr. Shannah Biggan, Dr. Jill Caffrey, Dr. Lauri Yablick, Dr. 
Geoffrey Ahern, Dr. Anne Herring, Dr. James Mortimer, Dr. Angela McBride, Dr. Brent 
Small, Dr. Donald Connor, Dr. Christine Belden, Dr. Elliott Mufson, and Dr. Kewei Chen. 
 
A very special thanks goes to Dr. Marwan Sabbagh who allowed me the opportunity to carry 
out and publish the studies contained in this thesis, along with several other articles that were 
not included.  The encouragement and mentorship he provided throughout the time we 
worked together was invaluable to my development as an investigator. 
 
To my wife, Amanda Malek-Ahmadi, whose love, support, and encouragement are 
cornerstones of my personal and professional lives. 
 
To my sons, Vincent, Roman, and Antonio, whose infinite energy and spirit are a constant 
inspiration to me. 
 
To my mother, Marjorie Malek-Ahmadi, whose unconditional love and support has carried 
me through my life. 
 
To my brother, John Malek-Ahmadi, who has always been there to give me support and 
encouragement in difficult times. 
 
And to my late father, Dr. Parviz Malek-Ahmadi (1943 – 2007), who I will always consider 







I declare that all material contained in this thesis is my own work.  Although this thesis is 
based on several peer-reviewed journal articles in which there were several co-authors, the 
compilation, integration, and interpretation of these studies represents my own work.  
6 
 
i. Preface – Author’s Contributions to the Published Works 
 The published works contained in this thesis are the result of a collaboration and 
mentorship that developed between myself and Dr. Marwan Sabbagh in February 2010. In 
2007, Dr. Sabbagh received a grant to conduct a pilot study of the Alzheimer’s Questionnaire 
(AQ), an instrument he developed. Data from three clinical sites was collected, analyzed, 
written-up, and submitted for publication without success. Dr. Sabbagh challenged me to re-
analyze the pilot data, significantly revise the manuscript, and attempt to submit it again for 
publication. With his mentorship and encouragement, we submitted a new version of the pilot 
study to Journal of Alzheimer’s Disease in June 2010 which was subsequently accepted for 
publication in August 2010. Over the next year, we began working the on validation study in 
which we added additional cases to the pilot data to achieve a sample size of 300 (100 
Normal Control, 100 Mild Cognitive Impairment, 100 Alzheimer’s Disease). For this study, 
Dr. Sabbagh once again charged me with analyzing the data and writing the manuscript. After 
submitting the paper to four different journals, it was finally accepted for publication in Age 
and Ageing, the official journal of the British Geriatrics Society.  
Concurrent to the work on this validation study, I thought of an idea for an additional 
analysis that would look at which items on the AQ best differentiated normal cognition from 
mild cognitive impairment. After putting together an abstract of the hypothesis with some 
preliminary analyses from the validation study data, Dr. Sabbagh enthusiastically supported 
me to follow through with the study. The analysis and writing of this paper was done 
concurrently with that of the validation study and the “item analysis study”, as we referred to 
it, was accepted for publication in BMC Geriatrics at around the same time that the validation 
study was accepted for publication. 
In 2012, after three successful publications with the AQ, Dr. Sabbagh was unsure 
about what direction to take regarding additional research on the instrument. The AQ had 
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recently been added to the battery of annual assessments in a large observational cohort study 
at our institute and after some thought, I proposed that we conduct a concurrent validity study 
to show how well the AQ correlated with established clinical measures of cognition and 
function in Alzheimer’s disease. By this time, Dr. Sabbagh and I had developed a very strong 
rapport with each other so it was understood by both of us that I would again undertake the 
data analysis and drafting of the manuscript. The paper was accepted into the first journal we 
submitted it to, Alzheimer’s Disease and Associated Disorders. It was at this point that Dr. 
Sabbagh allowed me a great deal of autonomy in terms of developing the hypotheses for 
further studies. 
The next study was very straight-forward and looked at how well the AQ correlated 
with established neuropsychological measures. For this study, Dr. Sabbagh also gave me the 
opportunity to work with and mentor a medical school student, Katherine Budolfson. 
Katherine and I collaborated together on the text of the manuscript and I also demonstrated 
the statistical analyses to her. This study was accepted for publication in Journal of 
Alzheimer’s Disease. 
The final study in this thesis looked at the longitudinal change of the AQ in 
cognitively normal, mild cognitive impairment, and Alzheimer’s disease cases. In this 
analysis, I collaborated with Dr. Kewei Chen of the Banner Alzheimer’s Institute on the 
statistical approach. His guidance was crucial to the success of this study and his mentorship 
help me improve my statistical knowledge and skills immensely. In early 2015, this paper 
was accepted for publication in Alzheimer’s Research and Therapy.  
In general, the published works on this thesis are largely my own work which 
included collaborations from other clinicians and research coordinators who are listed as co-




1.1 Overview of Alzheimer’s Disease 
 Alzheimer’s disease (AD) was first characterised pathologically in the early 20th 
century based on the neuropathological findings reported by Alois Alzheimer in a patient 
with significant cognitive and functional impairment. At autopsy, tissue samples from this 
patient’s cortex showed significant cortical degeneration, neuronal loss, and dense tangles of 
argyrophyillic strands. This constellation of neuropathological findings is now known to be 
derived from the deposition of amyloid plaques and neurofibrillary tangles which are now 
considered the neurpathological hallmarks of AD1. Although the neuropathological definition 
of AD has been well-characterised through more specific refinements in the 1990’s2-4, the 
clinical characterisation of AD continues to evolve.  
 The initial clinical manifestation of AD is often characterised by deficits in short-term 
memory which can include symptoms such as repeating statements and questions and 
difficulty remembering statements and instructions within a short period of time5. Other 
symptoms include difficulty with naming common objects and disorientation in familiar 
areas. The severity of AD is commonly stratified into a three-stage scheme consisting of 
mild, moderate, and severe stages6. Although other standardised schemes use up to seven 
stages7, the three-stage scheme may be more pragmatic for the purposes of diagnosis and 
treatment. The primary distinction between the mild, moderate, and severe stages is an 
individual’s functional status, although cognitive status is also given equal consideration 
when determining the stage of AD8. Individuals with mild AD often have a relatively high 
level of functioning in terms of daily activities such as grooming and basic household tasks6. 
In the moderate stage more pronounced functional deficits are often noted and it is in this 
stage where individuals may begin to demonstrate significant difficulty with basic activities 
in the areas of bathing and grooming while more difficult tasks in the areas of finance and 
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transportation are taken over by a caregiver, usually a spouse, significant other, or child of the 
individual6. In the severe stage both cognitive and functional abilities are impaired to a 
degree that the individual is often completely dependent on others for grooming, bathing, and 
eating. It is in this stage that individuals often lose the ability communicate and become bed-
ridden until the time of their demise6. 
 In most industrialised countries, AD is now considered to be a major public health 
problem in terms of its impact on individuals, their caregivers, and society at large. Currently 
it is estimated that there are between 4.5 and 5.5 million cases of AD in the United States 
(US)9 and 857,600 cases in United Kingdom (UK)10. By the year 2050 it is estimated that the 
prevalence of AD will be between 11 and 16 million in the US while prevalence in the UK is 
projected to be approximately one million by the year 2025. These estimates have significant 
implications for the utilisation of healthcare resources and pose a significant challenge for 
governments’ abilities manage the extraordinary economic impact that caring for these 
individuals will require. In 2015, total healthcare costs for the treatment and care of AD in the 
US was 217 billion USD (177,158,800,000 GBP). In the UK for the year 2014, these costs 
amounted to 26 million GBP. 
 The implications of the societal and economic impact of AD will be staggering if 
more effective methods of diagnosis and treatment are not implemented. In the US, the most 
recent drug to receive regulatory approval for use was memantine which received its approval 
for the treatment of moderate to severe AD in 2004. Since then, no additional drugs have 
been approved for the treatment of AD by the US Food and Drug Administration (FDA). In 
fact, many therapies that demonstrated efficacy in early-phase clinical trials failed to show a 
clinically meaningful benefit in large-scale efficacy trials11. A variety of reasons have been 
put forth as to why so many of these clinical trials failed: lack of decline in the placebo 
group12, lack of sensitivity to change in primary outcome measures13, and significant 
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variability between clinical sites participating in the trials14. Others have noted that biological 
markers used in some of the trials indicated that AD pathology did decrease during the 
treatment phase despite the absence of clinically meaningful change15. This finding has 
prompted many to believe that treatment for AD must be initiated prior to the onset of clinical 
symptoms. As a result, the field has begun to shift its attention to a classification referred to 
as mild cognitive impairment (MCI) which is thought to represent the prodromal stage of 
AD. 
 
1.2 Overview of MCI 
 Petersen et al16 published the first set of clinical criteria to be used in the diagnosis of 
MCI. These criteria were derived from a finding derived in the Canadian Health Study17 
which found that individuals with a Global Deterioration Scale (GDS)7 score of three were 
significantly more likely to develop AD than those with lower GDS scores. These individuals 
were thought to be in a transitional stage between normal age-related cognitive changes and 
AD. The MCI criteria proposed by Petersen et al16 provided more specificity on the 
psychometric identification of these individuals using the following criteria: a) individuals 
demonstrate significant subjective changes in cognition via self-report or informant-report, b) 
have an absence of functional impairment, and c) demonstrate memory test scores that are 1.5 
standard deviations below expected performance given their age and education and level. 
Petersen and colleagues also reported that the annual rate of conversion from MCI to AD was 
approximately 15%. 
 Since the publication of these criteria, several refinements have been made in order to 
provide more specificity with regard to those at risk for developing AD18. As a diagnostic 
entity, MCI is divided into two forms, amnestic (aMCI) and non-amnestic (naMCI). This 
subdivision was created in order to differentiate between individuals who demonstrate 
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impairments in memory as opposed to other cognitive domains such as attention, language, 
visuospatial perception, and complex reasoning/planning (also referred to as executive 
functions). The aMCI classification is used to represent individuals thought to be at the 
highest risk for developing AD while the naMCI classification is thought to represent 
cognitive dysfunction resulting from other non-AD dementia etiologies. Both the aMCI and 
naMCI classifications can be subdivided into single and multiple domain entities in order to 
further describe those who demonstrate impairment in only one cognitive domain or multiple 
cognitive domains.  
 
1.3 Epidemiology of MCI 
 In a recent study by Knopman and colleagues19 the prevalence of MCI was 21% in a 
subset (n = 6,471) of individuals who had been part of a larger longitudinal cohort. Of these 
MCI cases, AD was the primary or secondary etiology of impairment in 75% of these 
individuals. Additional evidence using pooled data from nine studies in varying geographical 
regions found a crude MCI prevalence of 5.9%, however the reported prevalence from each 
of the studies used in the analysis ranged from 5% to 37.6%20. In the same study, the 
prevalence of aMCI was 2% while the prevalence of naMCI was 3.9%20. Reported incidence 
rates of MCI have ranged from 27.7%21 to 70%22. Chen et al23 report that the progression rate 
from normal cognition to MCI is approximately 30% in a clinic-based sample while a 
substantially lower progression rate of 5% was found in a community-based sample. This 
difference in progression rates is likely the result a selection bias that is inherent in clinical 
populations as individuals with self-reported cognitive changes or a family history of AD 
more likely to be seek preventative or therapeutic interventions relative to the general 
population. Although individuals who receive a MCI diagnosis are more likely to progress to 
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AD, there is substantial evidence indicating that these individuals may revert to normal 
cognitive status in subsequent assessments24.   
 A number of different biological, demographic, and environmental risk factors for 
MCI have been identified. Older age, fewer years of formal education, having at least one 
copy of the APOE ε4 allele, personal history of type II diabetes, and personal history of 
stroke have all been implicated as risk factors for MCI25. Other studies have also reported on 
several vascular risk factors for MCI such as history of heart failure26, hypertension27, 
hyperlipidemia27, and coronary artery disease27. Others have also found that occupational 
exposure to pesticides associated with the development of AD28 which has been supported by 
animal studies demonstrating that exposure to several different pesticides was associated with 
the development of AD pathology29. A recent systematic review by Killin et al30 found that 
the evidence for pesticide exposure as a risk factor is strong while there is moderate evidence 
linking air pollution, aluminum, silicon, selenium, vitamin D deficiency, and electric and 
magnetic fields with an increased risk for AD. 
 Other studies have reported results for protective factors. Boyle et al31 report that 
individuals reporting greater purpose in life had a substantially lower risk of developing MCI. 
In terms of occupational factors, there is evidence suggesting that individuals whose work 
demands included information processing and pattern recognition had a significantly lower 
likelihood of developing AD relative to individuals whose occupations had lower cognitive 
demands32. Along these lines, continual engagement in mentally stimulating activities as well 







1.4 Evolution of MCI 
 In the years that followed the publication of the MCI diagnostic criteria, clinicians and 
researchers alike began to acknowledge that the utility of these criteria must go beyond that 
of simply increasing the accuracy of a clinical diagnosis. Shortly after the publication of these 
criteria the idea that MCI represented a therapeutic target began to take hold34 and during this 
time clinical trials involving MCI patients were initiated15. However, these trials also proved 
to be unsuccessful in showing a clinically meaningful benefit. In 2011, a consensus panel 
convened by the US National Institute of Health (NIH) made further refinements to the MCI 
classification35. In acknowledging the increased accuracy and utilisation of biological 
markers of AD pathology, the panel refined the criteria in which the classification of ‘MCI 
due to AD’ was proposed as a way to further increase the specificity of the MCI 
classification35. 
 The impact that these criteria have had on the field of MCI/AD research has prompted 
a significant shift in how therapeutic interventions are being approached. The most notable 
impact has been that AD prevention trials are now being conducted which enroll cognitively 
normal individuals who are at risk for developing AD by virtue of genetic and biomarker 
classification36,37. The rationale for treating asymptomatic individuals is that disease-
modifying therapies will yield the greatest therapeutic benefit when initiated early in the 
disease process so that the onset of clinical symptoms be delayed or halted completely. 
 Although the 2011 diagnostic criteria35 were intended to be used for research 
purposes, they do provide a more specific diagnostic context for clinicians as amyloid 
imaging scans are now available and have obtained regulatory approval for clinical use38. 
This has the potential to significantly increase a clinician’s confidence and accuracy in the 
clinical diagnosis of MCI due to AD. The inclusion of amyloid imaging within the formal 
workup for suspected cognitive impairment allows clinicians to begin making diagnoses of 
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inclusion as opposed to the typical diagnosis of exclusion. However, at the heart of the 
MCI/AD clinical diagnosis is the psychometric assessment of cognitive function which also 
continues to be refined39. 
 
1.5. Cognitive Assessment of MCI 
 In clinical settings, cognition is usually assessed using a battery of tests that measure 
performance in several different domains: memory, executive function, attention, visuospatial 
function, and language. This approach allows a clinician, usually a neuropsychologist, to 
discern patterns of performance among the tests to determine whether an individual’s 
performance is consistent with a particular clinical diagnosis40. However, general practice 
and geriatric specialists are often the first to see individuals for suspected cognitive 
impairment and often lack the resources to perform a comprehensive cognitive assessment in 
the context of the general care visit which is usually very brief in duration41,42. The Mini 
Mental State Exam (MMSE)43 was initially developed for hospital clinicians to conduct brief 
bedside assessments of cognition. The MMSE is comprised of 30 items that measure 
cognitive domains such as orientation, attention, memory, language, and visuoconstruction 
which yields a score with a range of 0 to 30. The MMSE was subsequently adopted and 
utilised by outpatient clinicians on a very large scale as its brief duration and simple 
administration procedures made it suitable for their clinical settings. As a result, the MMSE 
has been the most common and widely-known cognitive screening instrument among 
clinicians for some time. 
 However, as the focus of clinicians and researchers has shifted toward identifying 
people with more subtle cognitive deficits, the MMSE has shown to be relatively insensitive 
to milder levels of impairment44. In addition others have reported that performance on the 
MMSE is negatively impacted by lower levels of educational attainment and by floor and 
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ceiling effects45 which may result in false-positive indications of cognitive impairment. The 
reliability of the MMSE is also questionable as individual scores can vary by as much as 
three points within a two-month testing interval46. When diagnostic classification groups are 
applied the percent of individuals who retained the same classification at a follow-up 
assessment ranged from 58% to 78%46. Previous studies have indicated that scores ranging 
from 24 to 30 indicate normal cognition45, however more recent data using a very large 
sample size indicates that scores ranging from 26 to 30 are indicative of normal cognition47. 
In 2005, Nasreddine et al48 published a validation study of the Montreal Cognitive 
Assessment (MoCA) which is purported to be more sensitive to milder degrees of cognitive 
impairment. The initial validation study of the MoCA yielded a cutoff score of 26 indicating 
that scores of 25 and below are indicative of cognitive impairment. The MoCA’s 
administration procedures are similar to that of the MMSE where a variety of verbal and 
written tasks are administered to the individual in which the total score is based on the 
number of items correctly completed. As a result, the MoCA is now being widely-used in 
both research and clinical settings and has been translated into several different languages. 
 Previous research has demonstrated that the MoCA possesses greater accuracy in 
identifying MCI when compared to the MMSE. Damian et al49 found that the MoCA was 
superior to the MMSE in terms of sensitivity and specificity, but noted that the cutoff score 
used to determine whether impairment is present is likely dependent upon whether the 
assessment takes place in a general care or memory disorder clinic setting. In clinical 
specialist settings a higher cutoff score may be utilised as these individuals are more likely to 
be diagnosed with a memory disorder. However, in general care settings a lower a cutoff 
score may be used in order to minimise the number of undetected cases of cognitive 
impairment. Specifically, Damian et al49 suggest a lower cutoff score (24) than that indicated 
in the validation study45 provided optimal diagnostic accuracy for MCI. Freitas et al50 found 
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that diagnostic accuracy, as measured by area under the curve (AUC) value, for the MoCA in 
identifying MCI was 0.856 compared to the MMSE’s AUC value of 0.745 which was found 
to be significantly different (p < 0.001). Roalf et al51 found that the AUC values of the MoCA 
and MMSE were relatively similar with regard to differentiating MCI from normal cognition 
(MoCA AUC = 0.88; MMSE AUC = 0.84). However, these AUC values both increased to 
0.97 when the MMSE and MoCA were used in conjunction with an informant-based 
assessment of cognition.    
  
1.6 Informant-Based Assessments of MCI 
In addition to objective, performance-based assessments of cognition, informant-
based assessments of cognitive and functional ability are also used in clinical and research 
settings. One of the first informant-based assessments was introduced by Blessed et al52 and 
consisted of a semi-structured interview with an informant who had adequate knowledge and 
history of the individual’s cognitive and functional status. The questions contained in the 
assessment included items related to memory, daily functioning, and self-care. This 
assessment provided the impetus for many others to be developed, however the most 
ubiquitous has been the Clinical Dementia Rating (CDR)53. The CDR consists of a semi-
structured interview with the caregiver and a small number of performance-based 
assessments of memory, judgment, orientation, and calculations for the patient. The CDR is 
comprised of six domains (Memory, Orientation, Judgment and Problem Solving, Home and 
Hobbies, Community Affairs, Personal Care) that are used to assess various aspects of 
cognition and daily function. Each of the domains is scored on a scale using scores of 0, 0.5, 
1, 2, and 3 with higher scores indicating greater impairment in the domain. These scores are 
then added to create the Sum of Boxes score which is used as a summary score to indicate the 
degree of impairment. In addition to the Sum of Boxes score, the CDR Global Score is also 
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used in order to provide a categorical characterisation of cognitive status. The Global Score is 
derived from the individual domain scores and uses an algorithm to assign differing weights 
to each of the domain scores. The resulting categorisations are: 0 – Normal, 0.5 – 
Questionable Dementia, 1 – Mild Dementia, 2 – Moderate Dementia, 3 – Severe Dementia.  
The CDR has been used as an outcome measure in placebo-controlled trials54 as well 
as observational studies55. However, the amount of time need to administer the CDR ranges 
from 30 to 45 minutes which does not make it suitable for use in clinical settings. As a result, 
others have developed brief informant-based assessments of cognition that can be utilised in 
clinical settings. The AD856 and IQCODE57 are among the most common informant-based 
cognitive assessments that are designed to be both brief and accurate. Although the AD8 and 
IQCODE require substantially less time to administer than the CDR, their ability to 
accurately identify MCI is unclear. One study found that the AD8 demonstrated good 
diagnostic accuracy for individuals classified as 0.5 (Questionable Dementia) on the CDR56. 
Although this CDR classification is often used as a proxy for the MCI diagnosis58, it cannot 
be considered a fully equivalent proxy given that it lacks much of the information generally 
used when making the MCI diagnosis in a clinical setting. Published studies assessing the 
IQCODE’s accuracy in identifying MCI are conflicting with one study reporting negative 
results59 while another indicated relatively good diagnostic accuracy for MCI60. A direct 
comparison of the AD8 and IQCODE found that both measures accurately identified AD 
patients, but that the AD8 had higher accuracy for identifying MCI60. However, this study 
included only 13 MCI cases so these results require further study in order to fully validate 
their diagnostic accuracy for MCI. Based on these findings, it is unclear whether the AD8 or 
IQCODE can accurately differentiate clinically-diagnosed MCI individuals from those who 
are cognitively normal. As a result, there is a significant need for an informant-based 
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assessment of cognition has a short administration time and is accurate in identifying 
individuals with the earliest signs of cognitive impairment. 
 
1.7 Overview of the Alzheimer’s Questionnaire 
 The Alzheimer’s Questionnaire (AQ) is a clinician-administered and informant-based 
screening instrument that is designed to quickly and accurately detect cognitive impairment.  
The AQ consists of 21 yes/no questions that assess five domains of cognition function which 
are: Memory, Orientation, Functional Ability, Visuospatial and Language. Points for each 
question that are answered ‘yes’ are summed to give a total score which can range from 0 to 
27 with higher scores indicating greater impairment. 
Items for the AQ are similar to those contained in other widely used informant-based 
assessments53,56,57, but have been adapted for ease and speed of administration. Items for the 
AQ were selected and approved by a group of clinicians with extensive experience in 
dementia assessment. The items were selected based on their face validity to assess each of 
the AQ domains. Six items are weighted in the AQ total score with positive responses 
receiving two points instead of one as it was agreed by the clinicians that these items would 
clearly differentiate an impaired individual from a cognitively normal individual. 
 
2. Pilot Study 
 The initial pilot study61 of the AQ was undertaken by three clinicians practising in 
separate memory disorder clinics in the southwestern United States. The AD and MCI cases 
were drawn from these three clinic populations while data from a group of cognitively normal 
(CN) individuals was also collected for use as a reference group. The CN individuals were 
drawn from the Banner Sun Health Research Institute Brain and Body Donation Program 
located in Sun City, Arizona62. The AQ was administered to the informants of these study 
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participants as part of a battery that includes performance-based cognitive assessments, 
physical and neurological examinations, and other informant-based assessments that are 
given annually. 
The AD participants met NINCDS-ADRDA8 criteria for a clinical diagnosis of 
probable and possible Alzheimer disease. The CN cases were defined as having no 
limitations of activities of daily living by informant report and were within normal limits on 
neuropsychological testing. Petersen criteria was used in the diagnosis of MCI16. For the CN 
subjects, consensus diagnosis with a neurologist, geriatric psychiatrist, and neuropsychologist 
was used to determine the clinical status of each participant. Rigorous criteria were used to 
exclude anyone with any type of symptomatic or severe brain related neurological or 
psychiatric illness. Excluded conditions included developmental delay/learning difficulties, 
epilepsy, cerebral infarction or hemorrhage, multiple sclerosis, brain tumour, major 
depressive disorder (unipolar or bipolar), schizophrenia, traumatic brain injury, and substance 
abuse. The clinical diagnoses for the MCI and AD cases were carried out in a similar fashion 
as described above with the exception that one clinician was responsible for the diagnostic 
decision. None of the individuals included in the study had a MMSE score less than 20 so 
that MCI and AD cases would be representative of individuals that would be seen by a 
clinician for early cognitive problems. 
The sample consisted of 188 individuals (50 CN, 69 MCI, 69 AD) with an average 
age of 76.90±7.61 years and an average education level of 14.81±2.67 years. Gender 
distribution of the sample was of 45.7% (n = 86) females and 54.3% (n = 102) males. Initial 
psychometric analyses of the AQ showed that internal consistency was high as Cronbach’s 
alpha was equal to 0.88 and that the majority of interdomain correlations were moderate 
ranging from r = 0.41 to r = 0.66. Interdomain correlations for Memory and Orientation, 
Memory and Functional Ability, and Orientation and Functional Ability were all high (r = 
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0.80, r = 0.82, r = 0.81, respectively). All correlation values were statistically significant 
(p<0.001). After accounting for the effects of age and education, statistically significant 
differences on mean AQ scores were present between all three clinical groups [F = 177.85 df 
= (2, 185), p <0.001]. Diagnostic accuracy of the AQ was excellent for both AD and MCI and 
is shown in Table 1 below. Additional analyses were carried out in which the additional point 
for the weighted items was removed and found that the AQ’s diagnostic accuracy remained 
excellent for both MCI and AD (Table 2). 
 
Table 1. Pilot Study Diagnostic Accuracy Results for the AQ.  
 




86.96 (76.70 – 93.90) 
 
94.00 (83.50 – 98.7) 
 




98.55 (92.20 – 100.00) 
 
96.00 (86.30 – 99.50) 
 
0.99 (0.96 – 1.00) 
 
 
CI – Confidence Interval; MCI – Mild Cognitive Impairment; AD – Alzheimer’s Disease 
 
 
Table 2. Pilot Study Diagnostic Accuracy Results for the AQ Items Without Weightings. 
 




87.14 (77.00 – 93.90) 
 
92.73 (82.40 – 98.00) 
 




95.65 (87.80 – 99.10) 
 
98.18 (90.30 – 100.00) 
 
0.99 (0.96 – 1.00) 
 
 
CI – Confidence Interval; MCI – Mild Cognitive Impairment; AD – Alzheimer’s Disease 
 
The primary finding of this study is that the AQ can differentiate both MCI and AD 
from cognitively normal individuals with a very high degree of accuracy. The simplicity of 
administration and scoring coupled with its relatively short length suggest that AQ could be 
implemented very easily into care settings where rapid and accurate and assessments of 
cognitive function are needed. Although several other informant-based dementia 
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questionnaires have been developed, they have not been validated as accurate instruments in 
detecting individuals with MCI. This is important as identifying individuals in the earliest 
stages of cognitive decline will be necessary as the development of disease-modifying 
therapies become available.  
It is important to note that the AQ is not intended to replace a full diagnostic work-up 
that is typically administered when assessing individuals with memory problems. It should 
also be noted that the AQ was not used in a general practice setting so it is unclear whether 
the results of this study represent that of the general geriatric population. This study included 
patients who were seen by dementia specialists and as a result the sample used is biased to a 
certain extent. However, given its excellent diagnostic accuracy, ease of scoring, ease of 
administration, and short length of time needed for administration the AQ would be of great 
value to clinicians who have an extremely limited amount of time in order to assess 
individuals for memory and cognitive problems. 
 
3. Validation Study 
 The pilot study of the AQ was followed by a subsequent validation study63 that 
utilised the same sample, but added CN, MCI, and AD cases in order to achieve balanced 
group sizes that were sufficiently large. 50 CN, 31 MCI, and 31 AD cases were added so that 
the validation study had a final sample size of 300 (100 CN, 100 MCI, and 100 AD). The 
additional CN cases came from the Banner Sun Health Research Institute Brain and Body 
Donation Program62 while the additional MCI and AD cases were derived from one of the 
three memory clinics used in the pilot study. 
 This validation study extended upon the work of the pilot study by utilising additional 
measures of diagnostic accuracy, in the form of likelihood ratios, and also by establishing 
cut-off scores for each clinical group. The results of the diagnostic accuracy analyses of the 
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validation study mirrored those of the pilot study as the AQ, again, demonstrated excellent 
diagnostic accuracy for both MCI and AD (Table 3).  
 
Table 3.  Validation Study Diagnostic Accuracy Results of the AQ in MCI and AD. 
 













MCI 89.00  
(81.20 – 94.40) 
91.00  
(83.60 – 95.80) 
0.95  
(0.91 – 0.97) 
9.89  
(9.00 – 10.80) 
0.12 
(0.05 – 0.30) 
 5≤14 
AD 99.00  
(94.60 – 100.00) 
96.00  
(90.10 – 98.90) 
0.99  
(0.96 – 1.00) 
24.75  
(23.70 – 25.90) 
0.01 
(0.001 – .09) 
≥15 
CI – Confidence Interval; LR – Likelihood Ratio; MCI – Amnestic Mild Cognitive Impairment;  
AD – Alzheimer’s Disease 
 
The likelihood ratios provide further evidence of the AQ’s diagnostic accuracy as they 
are independent of the underlying prevalence of MCI and AD. Both the positive and negative 
likelihood ratios indicate that the AQ differentiates MCI and AD from normal cognition with 
a high degree of accuracy. The cutoff scores reported in the validation study are of significant 
value to clinicians as they provide an initial indication of where a patient may fall on the 
spectrum of cognitive impairment. Internal consistency of the AQ remained high as 
Cronbach’s alpha was 0.89 and the range of interdomain correlations was r = 0.45 to r = 0.69. 
The latter finding is very important as the moderate interdomain correlations indicate that 
each domain is measuring a unique construct and supports the argument that the AQ is 
capturing impairment in both cognitive and functional areas.  
However, it is noted that the use of the cutoff scores are not intended to replace the 
typical diagnostic workup that is carried out to exclude other possible causes of cognitive 
impairment that may be aetiologically different from AD. Although the cutoff scores do 
reflect diagnostic accuracy with regard to a rigorously-supported clinical diagnosis, use of the 
AQ score without the proper clinical context would be erroneous and could lead to incorrect 
diagnoses which would be unhelpful to a patient. However, results of the AQ may provide 
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important information regarding whether an individual is showing early signs of cognitive 
impairment. Although the AQ does not provide a specific diagnosis, its use as an early 
indicator of impairment may help clinicians make referrals for further work-up more quickly 
which could lead to earlier treatment and better prognosis. 
As the results of the pilot and validation studies showed that the AQ can differentiate 
MCI from normal cognition quite accurately, the next area of investigation sought to 
determine which individual AQ items drive its diagnostic accuracy.  
 
4. Item Analysis Study 
 Concurrent to the validation study63, a post-hoc analysis was carried out to determine 
which of the individual AQ items best differentiated MCI cases64. As additional data were 
being collected for the validation study, data from 47 MCI and 51 CN cases were used in this 
analysis. As expected, the majority of items had a greater proportion of positive responses for 
the MCI cases than the CN cases. However, more detailed analyses found that positive 
responses to four items were particularly strong predictors of MCI: repetition of statements 
and/or questions [OR 13.20 (3.02, 57.66)]; trouble knowing the day, date, month, year, and 
time [OR 17.97 (2.63, 122.77)]; difficulty managing finances [OR 11.60 (2.10, 63.99)]; and 











Table 4.  Analysis of Individual AQ Items as Predictors of MCI. 
 
AQ Item Odds Ratio 95% CI p-value 
Does the patient repeat questions or  
statements or stories in the same day? 
 
13.12 (3.02, 57.66) 0.001 
Does the patient frequently have trouble 
knowing the day, date, month, year, and 
time; or does the patient reference a 
newspaper or calendar for the date more 
than once a day? 
 
17.97 (2.63, 122.77) 0.003 
Excluding physical limitations, does the 
patient have trouble paying bills or doing 
finances; or are family members taking over 
because of concerns about ability? 
 
11.60 (2.10, 63.99) 0.005 
Does the patient have a decreased sense of 
direction? 
5.84 (1.09, 32.30) 0.04 
 
Together, these four items demonstrated good accuracy in differentiating MCI as sensitivity 
was 80%, specificity was 82%, and area under the curve (AUC) was 0.94. In addition, these 
four items accounted for approximately 71% of the variance between MCI and CN cases. 
 Despite a relatively small sampling of MCI and CN cases, the results of this study 
provided quantitative evidence for specific cognitive symptoms that differentiate MCI from 
normal cognition. These results also provide clinicians with a degree of specificity and 
granularity that had not been previously reported in the context of the clinical presentation of 
MCI. However, the clinical presentation of MCI can be heterogeneous65 and it is quite likely 
that individuals who eventually receive a diagnosis of MCI may present with a symptom 
profile that is different than the one presented with these four AQ items.  
 
5. Concurrent Validity 
 After demonstrating the diagnostic accuracy of the AQ, assessing its concurrent 
validity with gold-standard assessments of cognition and function was necessary in to provide 
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additional clinical validation. The concurrent validity study66 was carried out in a sample of 
individuals from the Banner Sun Health Research Institute Brain and Body Donation 
Program62. The sample of 146 individuals included 73 CN, 39 MCI, and 34 AD cases. The 
MCI and AD individuals were matched with a CN individual on age, gender, and education. 
The AQ was compared with the CDR Sum of Boxes, CDR Global Score, MoCA, and the 
MMSE. These particular measures were chosen because of their wide use in clinical and 
research settings so establishing the AQ’s correlation with these measures would provide a 
thorough assessment of the AQ’s validity. Concurrent validity was assessed primarily 
through Spearman correlations between the AQ and the reference assessments, however ROC 
analyses were also used to compare the diagnostic accuracy of the AQ with the other 
assessments.  
The AQ correlated strongly with the CDR-Sum of Boxes (r = 0.79) while moderate 
correlations were noted with the MMSE (r = -0.56) and MoCA (r = -0.46). Table 5 displays 
the AUC values with 95% confidence intervals for each of the instruments for all clinical 
groups. The AQ, MoCA, and MMSE demonstrated comparable AUC values for both MCI 
and AD. When the MCI and AD groups were combined all instruments showed favourable 
diagnostic accuracy with AQ showing slightly better performance than the MoCA and 
MMSE. The CDR-SOB was superior to all of the instruments in terms of diagnostic 
accuracy, however this is likely because it was used as a component of the consensus 













Table 5: Diagnostic Accuracy Comparison of AQ, CDR-SOB, MMSE, and MoCA  
 




0.74 (0.62, 0.83) 
 
0.99 (0.91, 1.00) 
 
0.81 (0.72, 0.87) 
CDR-SOB* 0.87 (0.77, 0.94) 0.99 (0.92, 1.00) 0.89 (0.82, 0.94) 
MMSE  0.76 (0.64, 0.85) 0.97 (0.87, 1.00) 0.80 (0.72, 0.87) 
MoCA  0.71 (0.60, 0.81) 0.94 (0.82, 0.99) 0.78 (0.70, 0.85) 
AUC (95% CI) 
 
*CDR-SOB was used to make consensus diagnosis 
 
 
 An additional analysis was carried out to characterise the AQ’s performance when 
participants were grouped according to their Global Score on the CDR (CDR 0 [n = 66]; 
CDR 0.5 [n = 49]; CDR 1, 2, 3 [n = 31]). Individuals with a CDR Global Score of 1, 2 and 3 
were combined as these three subgroups were not significantly different from each other 
when compared separately on the AQ total score. A statistically significant difference for the 
AQ total score was noted between the three CDR Global Score groups (Kruskall-Wallis = 
82.35 (df = 2) p<0.001; all groupwise comparisons p<0.001; Figure 1). Cohen’s d was used 
to assess the effect sizes of these group differences and found large effect sizes for all of the 
group comparisons: CDR 0 vs. CDR 0.5 = 1.27; CDR 0 vs CDR 1, 2, 3 = 3.70; CDR 0.5 vs. 














Figure 1. AQ Performance for CDR Global Score Groupings. 
The results of the concurrent validity study demonstrated that the AQ is comparable 
to other commonly used informant-based and patient-based measures in terms of its ability to 
differentiate MCI and AD patients from those who are cognitively normal. The large group 
differences noted for the CDR Global Score comparison provide an additional level of 
clinical validation to the AQ since the CDR is intended to correspond to a clinical diagnosis. 
It was noted that the AQ’s AUC value was lower than what was originally found in the 
validation study. This is likely due to the use of a smaller sample size in the current study, but 
also because clinical status was determined via consensus diagnosis rather than a clinical 
diagnosis. Although the consensus diagnosis is intended to correspond to a clinical diagnosis, 
since multiple clinicians are involved in a consensus diagnosis differing opinions and clinical 
interpretations among the clinicians may yield differing diagnostic categorisations than would 






6. Neuropsychological Correlates 
 The next study extended upon the concurrent validity study and determined how well 
the AQ correlated with neuropsychological and cognitive screening tests67. Since 
neuropsychological tests are utilised in making differential clinical diagnoses of MCI and 
AD, determining the extent to which the AQ correlates with objective and specific measures 
of various cognitive domains is needed in order further validate its ability to detect cognitive 
changes associated with MCI and AD. Specifically, the study aimed to determine whether the 
AQ corresponds to the neuropsychological phenotype of MCI due to AD in which memory 
and executive functions are most often impaired68. 
 This study utilised a larger sample of individuals (N = 300) from the Banner Sun 
Health Research Institute Brain and Body Donation Program62. Individuals diagnosed with 
MCI (n = 83) and AD (n = 67) were matched on age, gender, and education to a CN 
individual (n = 150). A large set of neuropsychological tests was used for the study which 
included: MMSE, MoCA, Mattis Dementia Rating Scale-2 (DRS-2), Clock Drawing Test, 
Rey Auditory Verbal Learning Test (AVLT), Brief Visuospatial Memory Test (BVMT), 
Trails A, Trails B, Digit Span (forward and backward), Controlled Oral Word Association 
Test (COWAT), Animal Fluency, Stroop Color/Word, Judgment of Line Orientation (JLO), 
Block Design, and the Boston Naming Test 30 Item (BNT-30).  
Spearman correlation analyses were carried out to assess the linear associations 
between the AQ and the neuropsychological measures. Data for DRS-2 and Block Design 
were only available from smaller subsets of the study sample (DRS-2 n = 79, Block Design n 
= 55). In order to minimise the impact of floor and ceiling effects from the AD and CN 
groups on neuropsychological tests, the CN, MCI, and AD groups were analysed together. 
This also allowed for the relationship between the AQ and the individual cognitive tests to be 
assessed on a continuum of cognitive impairment. 
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The percentage of variance accounted for by each cognitive test in the AQ score was 
determined by using robust least median squares regression models with AQ score as the 
outcome and cognitive test as the predictor. Each test was modelled independently in order to 
obtain a R2 value that was unique to each of the tests. 
The additional predictive value of the AQ in MCI for a select subset of tests was 
assessed through a series of logistic regression models. The first series of models used only 
the cognitive test score as predictor with CN/MCI as the outcome.  A second series of models 
included the AQ score along with the cognitive test. Area under the curve (AUC) values 
between the first and second models were compared in order to determine if the AQ added a 
significant amount diagnostic accuracy when combined with a cognitive test. All models 
included the GDS score in order to account for the effect of depressive symptoms on 
cognitive performance. Although measures of anxiety were not used in this study, the co-
occurrence of depressive and anxiety symptoms in older adults is quite common69 so it is 
possible that the presence of anxiety may have manifested in positive responses to the 
presence of depressive symptoms.   
Correlations between the AQ and the individual cognitive measures are shown in 
Table 6. The AQ correlated strongly with DRS-2 Total (r = -0.72) and the MMSE (-0.71). 
The AQ showed a moderate correlation with the MoCA (r = -0.68) and a weak correlation 
with Clock Draw (r = -0.32). The AQ also demonstrated moderate correlations with measures 
of memory and executive function, as lower performance on the memory measures was 
associated with greater reported impairment on the AQ. For the measures of attention, the AQ 
correlated moderately with Trails-A, but demonstrated weak correlations with Digit Span 
Forward and Digit Span Backward. Both language measures also correlated moderately with 
the AQ. For visuospatial function, the JLO demonstrated a weak correlation with the AQ 
while Block Design demonstrated no correlation. Measures of general cognition, memory, 
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and executive function each accounted for a substantial proportion of variance in the AQ 
score. The latter finding is extremely important as the domains of memory and executive 
function are often affected most prominently in AD. In addition, the finding that measures of 
general cognition accounted for a large portion of the variance is important as these 
assessments are often given in general practice settings so it is important that the AQ 





Table 6. Correlation Values for Neuropsychological Tests with the AQ 
 
Domain Test Correlation with AQ p-value R2 
General Cognition     
 MMSE -0.71 <0.001 0.63 
 MoCA -0.68 <0.001 0.57 
 DRS-2 -0.72 <0.001 0.71 
 Clock Draw -0.38 <0.001 0.31 
Memory     
 AVLT Total -0.62 <0.001 0.44 
 AVLT Delayed 
Recall 
-0.61 <0.001 0.43 
 BVMT-R Total -0.61 <0.001 0.41 
 BVMT-R Delayed 
Recall 
-0.65 <0.001 0.49 
Executive Function     
 Trails B 0.53 <0.001 0.52 
 Stroop Color/Word -0.51 <0.001 0.32 
 COWAT -0.27 <0.001 0.11 
Attention     
 Trails A 0.52 <0.001 0.41 
 Digit Span Forward -0.21 <0.001 0.06 
 Digit Span 
Backward 
-0.37 <0.001 0.18 
Language     
 BNT -0.44 <0.001 0.14 
 Animal Fluency -0.56 <0.001 0.41 
Visuospatial     
 Block Design -0.24 0.08 ---- 
 JLO -0.28 <0.001 0.11 
 
R2 value derived from least median squares regression model; R2 for Block Design could not 
be derived due to missing data among AD cases. 
 
 
Analyses showing the added diagnostic value of the AQ with select cognitive tests are 
shown in Table 7. For these analyses, we selected measures of general cognition and delayed 
recall memory measures as they are often used independently to differentiate clinical groups 
while many of the other domain-specific cognitive tests are often used in a broader diagnostic 
framework and interpreted in relation to other tests. We chose to limit our analyses to CN 
versus MCI cases as they would provide the most informative classification data given that 
research has shifted toward identifying individuals in the pre-clinical stages of the disease. 
On its own, the AQ demonstrated good diagnostic accuracy for MCI [AUC = 0.83, 95% CI: 
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(0.77, 0.88)]. When used in combination with different cognitive tests, the only test which 
showed significant benefit of the AQ’s addition was the MMSE as the AUC value 
significantly improved. 
  
Table 7. Additional Diagnostic Accuracy of Select Cognitive Tests with AQ in MCI 
Cases. 
 




AUC = 0.83 









AUC = 0.90 
95% CI: (0.80, 0.96) 
 
 
AUC = 0.94 






AUC = 0.79 
95% CI: (0.73, 0.85) 
 
 
AUC = 0.88 






AUC = 0.87 
95% CI: (0.80, 0.92) 
 
 
AUC = 0.90 




AVLT Delayed Recall 
 
AUC = 0.94 
95% CI: (0.90, 0.97) 
 
 
AUC = 0.97 




BVMT-R Delayed Recall 
 
AUC = 0.87 
95% CI: (0.82, 0.91) 
 
 
AUC = 0.91 




The results of this study demonstrate that the AQ correlates well with several 
performance-based neuropsychological and cognitive screening tests commonly used in 
clinical settings. The AQ demonstrated some weak correlations with several 
neuropsychological tests examining specific domains; however several moderate correlations 
were also noted, particularly with measures of memory and executive function. Given that 
decreased memory and dual processing skills are hallmark features that direct a clinician to a 
diagnosis of AD, these results suggest that the AQ is accurately assessing AD-specific 
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cognitive declines. Weak correlations between informant-reported measures and domain-
specific neuropsychological tests may be expected to some extent given that informant-based 
measures often contain items spanning several cognitive domains. Thus, the lack of overlap 
in the constructs measured by broad informant-based and domain-specific 
neuropsychological measures may explain weak correlations between these assessment types. 
Additionally, as some of these domains, such as visuospatial, are not typically 
expected to have significant involvement in AD, one would expect the AQ to have lower 
correlations with these domains than those with declines more strongly associated with AD, 
such as memory and executive function. It is noted that other measures such as, recognition 
memory, intrusions and repetitions on verbal memory, reduced primacy effect on verbal 
memory were not analyzed with the AQ. These measures are also thought to contribute to the 
neuropsychological profile of MCI and AD70 and may have provided additional clinical 
validation of the AQ. In addition, specific subtests of the cognitive and neuropsychological 
measures were not correlated with the AQ. Orientation and memory subsections of the 
MMSE, MoCA, and DRS-2 may have contributed more to the correlations with the AQ given 
that these items on the AQ accurately differentiated MCI from normal cognition64. 
These findings provide further evidence to support the clinical validity of the AQ as 
an instrument for detecting cognitive impairment associated with MCI and AD. In particular, 
the AQ demonstrated moderate correlations with memory and executive function measures 
which shows that the AQ can reasonably assess cognitive impairment demonstrated on 
standard neuropsychological measures. 
 
7. Longitudinal Change  
 Following the clinical validation studies, an examination of the AQ’s ability to 
measure change over time was carried out71. A major issue that both clinicians and 
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researchers often contend with is the degree to which a particular instrument is sensitive to 
change over time. For clinicians the results yielded from an assessment are often used to 
make decisions regarding treatment and resource use (i.e., assisted living, in-home care, etc.). 
For researchers and clinical trial specialists, the issue of sensitivity to change for a particular 
instrument has significant ramifications for whether or not a meaningful treatment effect will 
be detected between placebo and treatment groups in a clinical trial. 
The first aim of this study was to assess the sensitivity to change of the AQ in 
comparison to the MMSE, MoCA, and the Functional Activities Questionnaire (FAQ)72. The 
second aim of the study was to determine how well the AQ predicts global change as 
measured by the Functional Assessment Staging Test73 (FAST), GDS, and the CDR Global 
Score. Data from the two most recent annual visits for 202 individuals from the Banner Sun 
Health Research Institute Brain and Body Donation Program62 were utilised for this study. Of 
the 202 individuals, 101 were classified as cognitively normal (CN), 62 were classified as 
mild cognitive impairment (MCI), and 39 were classified as Alzheimer’s disease (AD). Each 
MCI and AD individual was matched on age, education, and gender to a CN individual, 
without replacement. 
The analyses investigating the sensitivity to change utilised a method similar to that of 
Costa et al74 which was completed through the calculation of a Cohen’s d effect size used for 
correlated designs75,76. Logistic regression analyses were used to assess the predictive value 
of the AQ, FAQ, and MMSE change scores on increases in FAST, GDS, or CDR Global 
Score. In the MCI group the AQ, FAQ, and MMSE all demonstrated small sensitivity to 
change in terms of their respective d values (0.33, 0.35, 0.24). In the AD group, the AQ 
demonstrated small sensitivity to change (d = 0.43), however the FAQ showed large 
sensitivity to change (d = 0.84) and the MMSE demonstrated moderate sensitivity to change 
(d = 0.52). In the CN group all three measures demonstrated small effect sizes (AQ: d = 0.18, 
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FAQ: d = 0.15, MMSE d = 0.02). Analyses that pooled the CN, MCI, and AD groups found 
that the AQ and FAQ demonstrated small, but significant associations with CDR Global 
Score increases (AQ [OR = 1.20 (1.09, 1.32), p<0.001]; FAQ [OR = 1.21 (1.11, 1.33), 
p<0.001]). The pooled analysis also yielded a small, but significant association for FAQ 
mean change and GDS increase [OR = 1.16 (1.06, 1.26), p = 0.001]. When clinically 
meaningful change was characterised with the reliable change index (RCI) the AQ was able 
to identify a higher percentage (24%) of MCI cases relative to the FAQ and MMSE (both 
17%). 
Although the effect sizes reported in this study are relatively small, they are consistent 
with the notion that cognitive changes associated with MCI and AD are often subtle and 
difficult to detect from a psychometric standpoint. This point is a major challenge for 
researchers and clinical trial specialists as the variability of cognitive tests is often 
numerically similar to the rate of change77. Informant-based instruments that assess 
functional ability are also prone to high degrees of variability due to varying pre-morbid 
levels of function and gender differences in the degree of participation for many functional 
activities that are assessed77. The degree to which a particular cognitive or functional measure 
is responsive to changes in disease status is extremely important, particularly in pre-
symptomatic and MCI populations where cognitive decline is slower and more subtle78.  
The results of this study indicate that the AQ demonstrated small sensitivity to 
longitudinal cognitive changes associated with MCI and AD. The AQ’s sensitivity to change 
in MCI was comparable to the FAQ while both instruments outperformed the MMSE in 
terms of effect size. The AQ was also significantly associated with longitudinal decreases in 
global cognition and function. Although the AQ’s sensitivity to change was small, it is 
possible that its sensitivity to change may be enhanced when used in conjunction with 




This series of studies demonstrated that the AQ is an informant-based cognitive 
assessment that can accurately identify individuals with cognitive impairment that is 
consistent with MCI and AD. The initial validation studies of the AQ demonstrated high 
diagnostic accuracy for both MCI and AD (Sabbagh MN, Malek-Ahmadi M, Kataria R, 
Belden CM, Connor DJ, Pearson C, Jacobson S, Davis K, Yaari R, Singh U. The Alzheimer’s 
Questionnaire: A proof of concept study for a new informant-based dementia assessment.  
Journal of Alzheimer’s Disease 2010;22(3):1015-1021; Malek-Ahmadi M, Davis K, Belden 
CM, Laizure B, Jacobson SA, Yaari R, Singh U, Sabbagh MN.  Validation and diagnostic 
accuracy of the Alzheimer’s Questionnaire (AQ). Age and Ageing 2012;41(3):396-399; 
Malek-Ahmadi M, Davis K, Belden CM, Jacobson SA, Sabbagh MN. Informant-reported 
cognitive symptoms that predict amnestic mild cognitive impairment. BMC Geriatrics 
2012;12:3) while subsequent studies provided ample evidence for its clinical validity through 
correlations with other established cognitive and informant-based instruments (Malek-
Ahmadi M, Davis K, Belden C, Sabbagh MN. Comparative analysis of the Alzheimer’s 
Questionnaire (AQ) with the CDR Sum of Boxes, MoCA, and MMSE. Alzheimer’s Disease 
and Associated Disorders 2014;28(3):296-298). The AQ’s correlations with standard 
neuropsychological tests provided additional evidence for its clinical validity by 
demonstrating specificity for the cognitive phenotype of MCI due to AD (Budolfson K, 
Malek-Ahmadi M, Belden C, Powell J, Davis K, Jacobson SA, Sabbagh MN. 
Neuropsychological correlates of the Alzheimer’s Questionnaire (AQ). Journal of 
Alzheimer’s Disease 2015;46(2):389-397). In terms of detecting longitudinal changes, the AQ 
demonstrated higher sensitivity to change relative to the MMSE and was also able to detect a 
higher proportion of individuals with clinically meaningful change (Malek-Ahmadi M, Chen 
K, Davis K, Belden CM, Powell J, Jacobson SA, Sabbagh MN. Sensitivity to change and 
 37 
 
prediction of global change for the Alzheimer’s Questionnaire. Alzheimer's Research & 
Therapy 2015;7:1).  
The diagnostic and clinical value of the AQ has also been recognized at the 
policy/governmental level as it is listed as a recommended assessment for possible cognitive 
impairment in the British Columbia Ministry of Health Geriatric Assessment Guidelines79. 
The AQ’s inclusion in these guidelines is a strong statement about the value it can provide to 
geriatric clinicians in terms of its speed of administration and diagnostic accuracy.  
Additional work using the AQ was conducted by Salazar et al80 who used the AQ to 
detect cognitive impairment in a Spanish-speaking population. The Spanish translation of the 
AQ was deemed to be a “culture fair” screening instrument for MCI and was a strong 
predictor of the CDR-SOB. This study also found that the AQ was able to accurately 
differentiate individuals with MCI from those who are cognitively normal and was also found 
to be biased toward the detection of memory impairment, which could be advantageous when 
used in pre-clinical AD populations. Given that research in the areas of MCI and AD has 
shifted toward identifying individuals in earlier stages of the disease36,37,81 utilising an 
informant-based instrument that is sensitive to the subtle cognitive changes that differentiate 
normal cognition from MCI is important. Although the results of AQ studies demonstrate that 
it can accurately differentiate MCI and AD from normal cognition with a high degree of 
accuracy, it has also been reported that it can add predictive value when used with other 
performance-based neuropsychological assessments67. Others have also noted that the 
addition of informant-based assessments with neuropsychological assessments provide a 
significant amount of added predicted value82 so it is likely that geriatric and memory 
disorder clinicians could benefit from using the AQ in conjunction with performance-based 
neuropsychological assessments such as the MMSE and the MoCA.  
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Clinicians often encounter cases where individuals with high educational and 
occupational attainment may perform within normal limits on objective cognitive tests, but 
are clearly demonstrating cognitive and functional deficits as reported by spouses and other 
informants. This dichotomy of cognitive and functional status is not uncommon and presents 
a significant diagnostic challenge to clinicians. In these instances, the AQ may be extremely 
useful to clinicians as informant-based reports of cognitive changes are less susceptible to the 
effects of cognitive reserve84 where performance on objective cognitive tests may be within 
normal limits. In addition, the use of informant-based measures help alleviate biases of self-
reported cognitive changes that may be due to factors unrelated to MCI and AD such as age-
related changes, lifestyle changes, stress, and other factors. In some cases, the patient may 
deny having any cognitive problems. Although the latter is often associated with clinical AD, 
anosognosia can also occur in MCI patients85. When a patient denies the presence of 
cognitive decline, informant-based information can help the clinician to glean a more 
accurate picture of a patient’s cognitive status. 
In the context of identifying individuals with MCI, a number of other challenges 
remain which clinicians and researchers must contend with. One of the main challenges to 
obtaining an accurate MCI diagnosis is that the diagnosis itself has a high degree of temporal 
instability. Specifically, the occurrence of reversion from MCI to normal cognition has been 
documented in several longitudinal studies and was recently summarised in two meta 
analyses24,86. Malek-Ahmadi24 summarised the reversion rates from 25 longitudinal studies 
and found that 24% of individuals who received a MCI diagnosis at their first assessment 
were classified as cognitively normal at their second assessment. A variety of factors appear 
to underlie this phenomenon, however the setting in which the study took place (community-
based vs. clinic) is thought to be one of the biggest determinants of reversion as community-
based studies had a substantially higher reversion rate (31%) relative to clinic-based studies 
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(14%). One possible explanation for this difference was proposed by Petersen et al87 who 
point out that clinic-based samples tend to have greater cognitive impairment and greater 
likelihood of disease progression when compared to community-based samples which could 
explain the lower reversion rates in clinic-based studies. The underlying difference in the risk 
of progression to MCI and AD in clinic-based samples is referred to as Berkson’s bias88, 
which is one type of selection bias. Since individuals who are seen in memory clinics are 
likely to have a significant family history of AD or feel that that they are already 
symptomatic, this results in clinic-based samples consisting of individuals with a higher 
baseline risk for progression to MCI and AD than individuals in community-based studies. 
As result, clinic-based samples are likely to have lower rates of reversion to normal cognition 
due to the nature in which individuals are recruited. This point has significant implications 
for cognitive screening tests as it has been shown that their diagnostic accuracy can be 
substantially lower when administered in settings where the prevalence of MCI and AD is 
low89. Other factors such as recovery from illness, improvement of depressive symptoms, 
anxiety and/or lack of familiarity with cognitive testing at the initial assessment90 are also 
thought to increase the likelihood of reversion. In addition, practice effects on 
neuropsychological tests may also contribute significantly to whether an individual reverts to 
a classification of normal cognition from MCI91-94. Since frequent neuropsychological 
assessments occur in both clinic-based and community-based studies, both types of studies 
are prone to the negative impact that practice effects have on discerning significant cognitive 
changes94.  
Although the instability of the MCI diagnosis is problematic for clinicians and 
researchers, this uncertainty can also have a profound impact on the patients themselves 
along with their families. Many clinicians are often reluctant to give a diagnosis of MCI as its 
ambiguity and uncertainty may cause unneeded worry and anxiety in their patients95. In 
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addition, there is often a negative stigma associated with MCI and in general, dementia 
diagnoses96. This stigma can occur at a public level where the general population may hold a 
negative view towards those with a particular diagnosis. However, the stigma for MCI and 
dementia also occurs at the personal level and may manifest as fear and anxiety which can 
lead an individual to decrease their socialization and to be more hesitant to seek specialised 
care for their condition96. Additional factors such as the inability of persons with more 
advanced AD to fully understand and remember the diagnosis, the potential for adverse 
psychological reactions, and the absence of effective treatments are reasons that many 
clinicians have cited as the rationale for not disclosing the AD diagnosis to their patients97. 
However, through the refinement of clinical diagnostic criteria, available treatments with 
modest efficacy, along with a societal emphasis on an individual’s autonomy, the vast 
majority of clinicians now regularly disclose AD diagnoses to their patients97.  
Disclosure of a MCI diagnosis has also proven to be challenging in clinical settings. 
This is primarily because MCI was initially characterised as a research diagnosis to identify 
individuals who were thought be at high-risk for developing AD97. However, the use of MCI 
as a diagnostic entity in clinical practice has been established for some time now. This is 
evident by the Diagnostic and Statistical Manual 5th edition (DSM-5) which now includes 
mild neurocognitive disorder (mNCD)98 and use of the mild cognitive disorder (MCD) 
diagnosis in the International Statistical Classification of Disease and Related Public Health 
Problems 10th edition (ICD-10)99. For the patient, the MCI diagnosis can still illicit a great 
deal of psychological discomfort although recent research suggests that proactive 
interventions directed toward depressive and anxiety symptoms may be helpful as well as 
addressing quality of life issues that may be impacted by a MCI diagnosis100. Furthermore, 
the diagnostic process for MCI allows clinicians the opportunity to implement cognitive 
 41 
 
rehabilitation strategies while the patient is cognitively fit enough to understand and carry out 
the strategies. 
 As the field has shifted toward identifying individuals in the pre-clinical or 
asymptomatic stage of AD, many of the same ethical issues associated with the MCI and AD 
diagnoses are still present, but have an added layer of complexity given the lack of clinical 
symptoms and relative uncertainty about disease progression. Currently, pre-clinical AD is 
determined based on the presence of abnormal biomarkers101 (fluid markers, protein markers, 
neuroimaging markers) that indicate the presence of disease pathology in the absence of overt 
clinical symptoms. Although these individuals are thought to be at an increased risk for 
developing MCI and AD, biomarker measurements currently in use do not have the 
prognostic certainty to definitively inform an individual that clinical disease progression is 
imminent. As a result, the disclosure of “biomarker positive” results puts clinicians and 
researchers in a very difficult position when attempting to explain the meaning of these 
results to patients and research participants101. In particular, disclosure of one’s genotype for 
the apolipoprotein E (APOE) gene has been the source of significant debate among clinicians 
who treat MCI and AD patients102. Among the three APOE alleles (ε2, ε3, ε4) individuals 
who carry at least one copy of the ε4 allele are at an increased risk for developing AD101. 
Although the APOE ε4 genotype has shown the strongest and most consistent genetic risk for 
AD103, it is not deterministic as many individuals who are ε4 carriers will not develop AD 
and individuals who are ε2 or ε3 carriers can also develop AD. The interpretation of APOE 
ε4 status as a risk factor for AD must be emphasized and communicated clearly to individuals 
who choose to find out their APOE genotype. Since the primary function of the APOE gene 
is cholesterol transport103, it is very difficult to associate APOE’s function directly with AD 
pathogenesis. In addition, the APOE ε4 allele is also associated with cardiovascular disease104 
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which further underscores the importance of communicating one’s APOE genotype as a risk 
factor and not a determining factor.    
 However, even in this uncertain diagnostic context Caselli et al105 found in their 
survey of 4,036 individuals that approximately 70% of the respondents would opt for being 
tested to know their APOE ε4 carrier status even in the absence of an effective intervention 
for AD. The vast majority (94.9%) reported that they would be comfortable learning of their 
APOE ε4 genotype for the purposes of research study participation. When respondents were 
posed with the hypothetical scenario of finding out that they had an increased genetic risk of 
AD, most of the respondents (90.5%) stated they would pursue a healthier lifestyle, however 
11.6% reported that they would seriously consider suicide. The latter finding was explored 
further in an additional study by Caselli et al106 and found that individuals endorsing suicidal 
ideation were not clinically depressed, did not have high degrees of neuroticism, and had no 
indication of cognitive impairment. However, these individuals did report a significantly 
higher degree of non-support relative to those who did not endorse suicidal ideation. In order 
to mitigate the risk of suicide in these individuals, Caselli et al106 suggest that enrollment into 
a research study, participation in a support group, and close monitoring by a clinician may be 
helpful. The findings of these studies highlight the need to develop a framework for 
addressing the pre-clinical AD diagnosis from societal, legal, and socioeconomic 
perspectives107.    
 In light of the ethical issues surrounding the MCI diagnosis, it should be mentioned 
that there is currently no standard pharmacological treatment for MCI available. Although 
cholinesterase inhibitors are the standard treatment for clinical AD, they do not appear to 
have a beneficial effect on cognition in individuals with MCI108. In recent years, non-
pharmacological treatments have been tested in individuals with MCI and have had varying 
degrees of efficacy. A recent review by Horr et al109 found that randomized trials using 
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physical activity and cognitive interventions provided modest benefits, however more 
definitive conclusions could not be drawn due to significant variability in study design, 
outcome selection, and diagnostic criteria used for MCI. Others have suggested that 
mindfulness-based therapies may be effective as well110. An earlier review by Cotelli et al111 
indicated that many studies found positive benefits for non-pharmacological interventions 
when used in conjunction with cholinesterase inhibitor therapy. However, it is unclear how 
long the benefits of non-pharmacological interventions last and to what extent they provide 
neuroprotective effects from future disease progression. 
 
9. Conclusion 
 The series of studies that served to validate the use of the AQ demonstrate that it has a 
great deal of clinical value in terms of accurately identifying individuals with MCI and AD. 
In particular, its ability to accurately identify individuals with MCI is extremely important 
given that there is now an increased focus on identifying individuals in the earliest stages of 
the disease. In addition to the AQ’s excellent diagnostic accuracy, this series of studies also 
demonstrated that it correlates well with established measures of cognition and functional 
status. In particular, the AQ was associated with longitudinal changes in global cognition and 
was able to detect a higher proportion of MCI cases relative to other instruments. Although 
these studies firmly established the clinical validity of the AQ, additional studies are needed 
to determine how well the AQ corresponds with AD biomarkers. Given that there is now 
tremendous focus on pre-clinical AD, characterising the AQ’s performance in conjunction 
with AD biomarkers will be important in order to show that it can be used to detect the 
earliest cognitive changes so that therapeutic interventions can be initiated as quickly as 
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Abstract. The aim of this pilot study is to determine the feasibility and clinical utility of a brief, informant-based screening
questionnaire for Alzheimer’s disease (AD) that can be administered in a primary care setting. The Alzheimer’s Questionnaire
(AQ) was administered to the informants of 188 patients in 3 dementia clinics (50 cognitively normal, 69 mild cognitive impairment
(MCI), 69 AD). Total score for the AQ is based upon the sum of clinical symptom items in which the informant responds as
being present. Clinical symptoms which are known to be highly predictive of the clinical AD diagnosis are given greater weight
in the total AQ score. The mean time of administration of the AQ was 2.6 ± 0.6 minutes. Sensitivity and specificity were found
to be high for detecting both AD (98.55, 96.00) and MCI (86.96, 94.00) with ROC curves yielding AUC values of 0.99 and 0.95,
respectively. This pilot study indicates that the AQ is a brief, sensitive measure for detecting both MCI and AD and could be
easily implemented in a primary care setting.
Keywords: Alzheimer’s disease, instrument, questionnaire, primary care
INTRODUCTION
Confidence in making the diagnosis of Alzheimer’s
disease (AD) and mild cognitive impairment (MCI)
remains elusive. Evidence suggests that physicians,
bombarded by demands of care by increasing numbers
of medical conditions and available treatments, are not
sufficiently sensitive to signs of cognitive impairment
or early dementia.
Many physicians do not screen for cognitive prob-
lems in their practices unless they receive complaints
from either patients or patients’ families [1–3]. This is
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Roberts Center for Clinical Research, Banner Sun Health Research
Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA.
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unfortunate since a majority of patients with a dement-
ing illness do not report cognitive problems to their
health care providers and, on average, family members
do not seek medical attention for the patient until sev-
eral years after the onset of symptoms. As a result,
recognition of dementia by primary care physicians is
poor until it is moderately advanced [3,4]. Providers
cite a lack of confidence in diagnosing AD as a primary
reason that nearly half of AD patients remain undiag-
nosed [1,5,6]. Delaying diagnosis results in increased
likelihood of disease progression before intervention is
attempted [7]. Screening has been proposed to help
combat under-diagnosis but validated, structured, in-
terview based instruments are lacking. The desirable
characteristics for a clinician-administered screening
instrument include high sensitivity, high specificity,
short administration time, minimal training require-
ments for the instrument administrator and simplicity
of scoring [7].
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We have developed the Alzheimer’s Questionnaire
(AQ), a clinician-administered and informant-based
screening instrument as a way to quickly and accu-
rately detect cognitive impairment. Scores for some
items are weighted based on their ability to accurately
predict the clinical AD diagnosis which is made based
on the results from other validated instruments. The
AQ offers the advantage of asking simple yes/no ques-
tions in a weighted format that gives an absolute score
without requiring interpretation of individual domains.
This will aid clinicians in asking the most pertinent
questions when screening for cognitive decline in the
primary care setting [2].
METHODS
Development of the AQ
Items for the AQ are based on those from other
widely used informant-based assessments [8,10–12],
but have been adapted for ease and speed of adminis-
tration. Items for the AQ were selected and approved
by a group of clinicians with extensive experience in
dementia assessment. The items were selected based
on their face validity to assess each of the AQ domains.
Six items were selected to be weighted in the AQ total
score as it was agreed by the clinicians that these items
would clearly differentiate an impaired individual from
a cognitively normal individual.
Study participants
The AD and MCI subjects were drawn from the prac-
tices of three physicians (MS, RY, US). The cognitively
normal (NC) subjects were administered the AQ as part
of their annual assessment for a brain donation program
as all are required to provide a collateral informant.
Since this is a data gathering project, an IRB exemption
was granted.
Included in the study were 188 subjects, 50 of which
were designated NC, 69 were MCI cases, and 69 were
AD cases. The AD subject met NINCDS-ADRDA [13]
criteria for a clinical diagnosis of probable and possi-
ble AD. Our NC subjects were defined as having no
demonstrable cognitively-based limitations of activi-
ties of daily living including employment by informant
report. MCI cases were diagnosed as such based on Pe-
tersen criteria [14]. Consensus diagnosis with a neurol-
ogist, geriatric psychiatrist, and neuropsychologist was
used to determine the clinical status of each subject.
Rigorous criteria were used to exclude anyone with any
type of symptomatic or severe brain related neurologi-
cal or psychiatric illness. Excluded conditions includ-
ed mental retardation, epilepsy, cerebral infarction or
hemorrhage, multiple sclerosis, brain tumor, major de-
pressive disorder (unipolar or bipolar), schizophrenia,
traumatic brain injury, and substance abuse. This was
done by prospective interview of the participant and
careful scrutiny of the medical records. Each subject
was asked to identify an informant to provide additional
information on cognitive and functional changes.
Administration of AQ
The AQ consists of simple yes/no questions in a
weighted format pertaining to five domains which are:
Memory, Orientation, Functional Ability, Visuospatial
and Language (App 1). Points for each question that are
answered “yes” are summed to give a total score. Each
subject was accompanied by the informant to a clinic,
where the AQ was administered to the informants of
consecutive patients.
Statistical analysis
The data were analyzed by first evaluating the sensi-
tivity and specificity of the AQ with regard to identify-
ing both MCI and AD cases. The accuracy of the AQ
was then analyzed by using receiver operating charac-
teristic (ROC) curves and their associated area under
the curve (AUC) value. The psychometric properties
of the AQ were then analyzed through a principal com-
ponent factor analysis and by Cronbach’s alpha which
assessed the AQ’s internal validity. In addition, corre-
lations of the AQ domain scores were also derived in or-
der to demonstrate internal validity. Analysis of covari-
ance (ANCOVA) was also used to discern statistically
significant group differences in AQ scores between the
three clinical groups.
RESULTS
The AQ was administered to the informants 188 sub-
jects. Individuals with Mini-Mental Status Examina-
tion (MMSE) scores below 20 were excluded in or-
der reduce the amount of overall variability in the data
and so that the data better reflected a population that
is likely to be seen in a primary care setting for cogni-
tive complaints. The sample consisted of 45.7% (n =
86) females and 54.3% (n = 102) males. Detailed
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Table 1
Demographic Characteristics of Study Sample
NC MCI AD Total
N 50 69 69 188
Mean Age (sd) 77.60 (7.33) 74.61 (7.71) 78.68 (7.21) 76.90 (7.61)
Mean Education (sd) 15.48 (2.85) 14.61 (2.60) 14.52 (2.57) 14.81 (2.67)
Mean MMSE (sd) 28.86 (1.31) 27.28 (1.99) 24.09 (2.50) 26.53 (2.83)
Mean AQ Score (sd) 2.12 (2.31) 11.06 (5.12) 17.64 (4.84) 11.10 (7.53)
NC – Normal Control; MCI – Mild Cognitive Impairment; AD – Alzheimer’s Disease.
Table 2
Sensitivity, Specificity, and AUC of the AQ
Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)
MCI 86.96 (76.70–93.90) 94.00 (83.50–98.7) 0.95 (0.90–0.98)
AD 98.55 (92.20–100.00) 96.00 (86.30–99.50) 0.99 (0.96–1.00)
MCI – Mild Cognitive Impairment;
AD – Alzheimer’s Disease.
Fig. 1. ROC Curve for MCI (AUC = 0.95).
demographic characteristics are displayed in Table 1.
The mean time of administration of the AQ was 2.6 ±
0.6 minutes.
Sensitivity and specificity of the AQ were found to
be high for detecting both MCI and AD. In addition,
ROC curve analysis yielded high AUC values. Values
for sensitivity, specificity, and AUC are displayed in
Table 2. Graphical representations of the ROC analyses
are displayed in Figs 1 and 2. Internal validity of the
AQ was determined to be high as Cronbach’s alpha was
equal to 0.88. Factor analysis was conducted using the
principal component analysis method and showed that
all 21 items on the AQ loaded strongly onto one factor
which accounted for 33.26% of the total variance with
an Eigen value of 6.98.
Correlations between the domain scores of the AQ
were also evaluated to further demonstrate internal va-
lidity and are shown in Table 3. All correlation values
are significant at the p < 0.0001 level. Analysis of co-
Fig. 2. ROC Curve for NC versus AD (AUC = 0.99).
variance (ANCOVA) was used to analyze group differ-
ences on the AQ. After accounting for the effects of age
and education, statistically significant differences on
mean AQ score were present between all three clinical
groups [F = 177.85 df = (2, 185), p < 0.0001].
A separate analysis of the data was conducted with
the weights removed from the weighted items. In gen-
eral, removing the weights did not change sensitivity,
specificity, and AUC values (Table 4). Correlations
among the AQ domain scores were similar to those
found with weighted scores (Table 5). However, the
Language domain had notable increases in its correla-
tions with Memory, Orientation, and Functional Abil-
ity in the unweighted analysis. In addition, the factor
analysis results were almost identical to those of the
weighted analysis and Cronbach’s alpha was slightly
higher (0.89) for the unweighted analysis.
In addition, several items on the AQ that appeared to
be similar with respect to content and construct were
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Table 3
Correlation of AQ Domain Scores
Domain Memory Orientation Functional ability Visuospatial Language
Memory ———– 0.80 0.82 0.55 0.64
Orientation 0.80 ———– 0.81 0.59 0.63
Functional Ability 0.82 0.81 ———– 0.59 0.66
Visuospatial 0.55 0.59 0.59 ———– 0.41
Language 0.64 0.63 0.66 0.41 ———–
p-value for all correlations is significant at the 0.0001 level.
Table 4
Sensitivity, Specificity, and AUC of the AQ With Unweighted Items
Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)
MCI 87.14 (77.00–93.90) 92.73 (82.40–98.00) 0.94 (0.89–0.98)
AD 95.65 (87.80–99.10) 98.18 (90.30–100.00) 0.99 (0.96–1.00)
MCI – Mild Cognitive Impairment; AD – Alzheimer’s Disease.
Table 5
Correlation of AQ Domain Scores with Unweighted Items
Domain Memory Orientation Functional ability Visuospatial Language
Memory ———– 0.80 0.81 0.63 0.66
Orientation 0.80 ———– 0.80 0.65 0.64
Functional Ability 0.81 0.80 ———– 0.62 0.68
Visuospatial 0.63 0.65 0.62 ———– 0.44
Language 0.66 0.64 0.68 0.44 ———–
p-value for all correlations is significant at the 0.0001 level.
identified and analyzed to determine if any of the items
should be eliminated. These consisted of six questions
among three of the domains. Each domain contained
two questions that were identified for further analy-
sis. Kappa statistics were calculated for each pair of
questions to determine the extent to which they were
answered similarly.
For the Orientation domain, “Does the patient be-
come disoriented in unfamiliar places?” and “Does the
patient become more confused when travelling outside
the home?” yielded a Kappa of 0.34 (0.01, 0.67). For
the Visuospatial domain, “Is the patient getting lost in
familiar surroundings?” and “Does the patient have
a decreased sense of direction?” yielded a Kappa of
0.34 (0.05, 0.62). For the Language domain, “Does the
patient confuse names of family members or friends?”
and “Does the patient have difficulty recognizing peo-
ple who are familiar to him/her?” yielded a Kappa of
0.34 (0.01, 0.67).
DISCUSSION
Two important and conclusive findings are highlight-
ed within the present study. First, the AQ is a sensi-
tive measure for detecting both AD and MCI. Second,
the AQ is a time-efficient and easily administered tool
with a simple scoring system. As the time taken to
administer AQ is less than 3 minutes, making it easy to
implement in a primary care setting to screen for cog-
nitive problems. The simplicity of the AQ is reflected
in that the total score is easily calculated by summing
the number of items that have a “yes” response.
The rationale for weighting certain items on the AQ
is that they reflect the presence of cognitive symptoms
which are known to be highly predictive of the clini-
cal AD diagnosis, such as disorientation to time (e.g.,
day of the week, month) and repeating statements and
questions within a short period of time [15]. This dif-
ferentiates the AQ from other informant-based instru-
ments that give equal weight to all of their items as it
is then problematic to accurately differentiate cognitive
symptoms that are related to AD versus normal aging.
The result of utilizing weighted scores for those items
that are highly predictive of clinical AD is that high
diagnostic accuracy, as demonstrated by the sensitivity,
specificity, and ROC curves, is achieved which strong-
ly supports the clinical validity of AQ. In addition, this
study also demonstrated high internal validity of the
AQ through factor analysis and also with a high Cron-
bach’s alpha. Specifically, the factor analysis shows
that the items of the AQ accurately assess memory and
other cognitive components that are indicative of MCI
and AD.
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Table 6
Comparison of AQ Performance with AD8 and IQCODE in AD
Instrument Sensitivity Specificity AUC Cronbach’s alpha
AQ 98.55 96.00 0.99 0.88
AD8 85.00 [8] 86.00 [8] 0.83 [8] 0.86 [25]
IQCODE 79.00 [26] 82.00 [26] 0.85 [26] 0.93–0.97 [9]
Appendix 1. The Alzheimer’s Questionnaire
Yes No Weighted Score
Memory
Does the patient have memory loss? 1
If so, is their memory it worse than a few years ago? 1
Does the patient repeat questions OR statements OR stories in the same day? 2
Have you had to take over tracking events OR appointments? OR Does the patient forget appointments? 1
Does the patient misplace items more than once a month? OR Does the patient misplace objects so that he
or she cannot find them?
1
Does the patient suspect others are moving, hiding or stealing items when they cannot find them? 1
Orientation
Does the patient frequently have trouble knowing the day, date, month, year, time? OR Does the patient
have to use cues like the newspaper or the calendar to know the day and date more than once a day?
2
Does the patient become disoriented in unfamiliar places? 1
Does the patient become more confused outside the home or when traveling? 1
Functional Ability
Excluding physical limitations (e.g., tremor, hemiparesis, etc.), does the patient have trouble handling money
(tips, calculating change?)
1
Excluding physical limitations (e.g., tremor, hemiparesis, etc.), does the patient have trouble paying bills or
doing finances OR Are family members taking over finances because of concerns about ability?
2
Does the patient have trouble remembering to take medications or tracking medications taken? 1
Is the patient having difficulty driving? OR Are you concerned about the patient’s driving? OR Has the
patient stopped driving for reasons other than physical limitations?
1
Is the patient having trouble using appliances (e.g., microwave, oven, stove, remote control, telephone,
alarm clock)?
1
Excluding physical limitations, is the patient having difficulty in completing home repair or other home
related tasks (housekeeping)?
1
Excluding physical limitations, has the patient given up or significantly reduced activities such as golfing,
dancing, exercising, or crafts?
1
Visuospatial
Is the patient getting lost in familiar surroundings (own neighborhood)? 2
Does the patient have a decreased sense of direction? 1
Language
Does the patient have trouble finding words other than names? 1
Does the patient confuse names of family members or friends? 2
Does the patient have difficulty recognizing people familiar to him/her? 2
Analyses of the data without the weights showed no
significant differences among the statistical measures;
however the inclusion of weights on certain items ap-
pears to optimize sensitivity and overall diagnostic ac-
curacy for AD. The unweighted analysis also showed an
increase in correlation values among certain domains.
Specifically, the Language domain showed increased
correlations with Memory, Orientation, and Functional
Ability. The reason for this is unclear, but it is pos-
sible that removing the weights simply made the data
fit a more linear pattern. In addition, questions that
appeared to be overlapping in construct measurement
did not overlap as shown by the low rate of agreement
within the question pairs in each domain. Although
these items appear to be similar, they are measuring
distinct phenomena.
Although several other informant-based dementia
questionnaires have been developed, they have not been
validated as accurate instruments in detecting individu-
als with MCI. This is important as identifying individu-
als in the earliest stages of cognitive decline will be nec-
essary as the development of disease-modifying ther-
apies become available. Currently-used instruments
that are clinician administered such as the MMSE [16,
17], the neurobehavioral cognitive examination [18],
the 7 minute screen [19], the time and change test [20],
the memory impairment screen [21], the clock drawing
test [22], and the mini-cog [23] have demonstrated rela-
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tively good diagnostic ability in AD patients. However,
the ability of these instruments to identify individuals
with MCI is questionable.
In addition, currently used informant-based instru-
ments have not been shown to accurately identify
individuals with MCI. The most common clinician-
administered [16–23] and informant-based [8–12,24–
26] instruments have demonstrated specificities and
sensitivities exceeding 80% in identifying AD cases
and all take less than 10 minutes to administer. Rela-
tive to the most widely used of these instruments, the
AQ has higher sensitivity and specificity with regard to
identifying AD cases (Table 6), but also high sensitiv-
ity and specificity in identifying MCI. In addition, its
administration time is comparable and in many cases
takes less time to administer.
It is important to note that the AQ is not intended to
replace a full diagnostic work-up that is typically done
when assessing individuals with memory problems. It
should also be noted that the AQ was not used in a
general practice setting so it is unclear whether the re-
sults of this study represent that of the general geriatric
population. This study utilized patients who were seen
by dementia specialists and as a result the sample used
is biased to a certain extent. Although the ultimate goal
is to employ this instrument in general practice, it was
employed in specialty practices during this pilot study.
In spite of these shortcomings, the AQ may be an ex-
tremely useful tool to clinicians who require the use of
a brief and accurate assessment of cognition in order
to determine if a patient might require further evalu-
ation. Given its diagnostic accuracy, ease of scoring,
ease of administration, and short length of time needed
for administration the AQ would be of great value to
many clinicians who have an extremely limited amount
of time in order to assess individuals with memory and
cognitive problems.
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Abstract
Background: accurately identifying individuals with cognitive impairment is difﬁcult. Given the time constraints that many
clinicians face, assessment of cognitive status is often not undertaken. The intent of this study is to determine the diagnostic
accuracy of the Alzheimer’s questionnaire (AQ) in identifying individuals with mild cognitive impairment (MCI) and AD.
Methods: utilising a case–control design, 300 [100 AD, 100 MCI, 100 cognitively normal (CN)] older adults between the
ages of 53 and 93 from a neurology practice and a brain donation programme had the AQ administered to an informant.
Diagnostic accuracy was assessed through receiver-operating characteristic analysis, which yielded sensitivity, speciﬁcity and
area under the curve (AUC).
Results: the AQ demonstrated high sensitivity and speciﬁcity for detecting MCI [89.00 (81.20–94.40)]; [91.00 (83.60–
65.80)] and AD [99.00 (94.60–100.00)]; [96.00 (90.10–98.90)]. AUC values also indicated high diagnostic accuracy for both
MCI [0.95 (0.91–0.97)] and AD [0.99 (0.96–1.00)]. Internal consistency of the AQ was also high (Cronbach’s alpha = 0.89).
Conclusion: the AQ is a valid informant-based instrument for identifying cognitive impairment, which could be easily
implemented in a clinician’s practice. It has high sensitivity and speciﬁcity in detecting both MCI and AD and allows clini-
cians to quickly and accurately assess individuals with reported cognitive problems.
Keywords: mild cognitive impairment, Alzheimer’s disease, cognitive screening, informant-based assessment
Introduction
Given the expected increase in Alzheimer’s disease (AD)
prevalence in the USA [1] many clinicians will be faced
with the prospect of evaluating many individuals for pos-
sible cognitive impairment. This problem may be further
compounded by the possibility that screening for cognitive
impairment may become mandatory under proposed
healthcare reform [2]. Often, the ﬁrst clinician a patient
may see is a primary care physician who often has a limited
amount of time to assess the individual. In addition to time
constraints, many physicians do not screen for cognitive
problems unless they receive complaints from patients or
patients’ families [3–5]. As a result dementia is not
recognised by physicians until it is moderately advanced [6,
7]. Providers also cite a lack of conﬁdence in diagnosing
AD as a reason that nearly half of AD patients remain un-
diagnosed [3, 7, 8].
This necessitates the use of a brief and accurate screen-
ing instrument in order to determine, which patients
require further assessment. The most common tool used to
screen for dementia is the Mini-Mental Status Examination
(MMSE) [9]; however, its scores can be biased by education
level which can lead to false positive indications of impair-
ment for individuals with low educational attainment and
false negative indications of no impairment for highly edu-
cated individuals [10]. Informant-based questionnaires, such
as the AD8 [11], IQCODE [12] and the DQ [13], have
1
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been developed in order to quickly and accurately identify
clinical AD and have demonstrated good sensitivity
and speciﬁcity (please see Supplementary data available in
Age and Ageing online, Table S3). Although the Clinical
Dementia Rating (CDR) [14] is widely used in clinical re-
search settings, its utility in clinical practice is questionable
given the length of time necessary for administration.
The Alzheimer’s questionnaire (AQ) was designed to be
a brief and easily administered assessment for use with col-
lateral sources. A recent pilot study of the AQ demonstrated
high sensitivity and speciﬁcity for detecting mild cognitive
impairment (MCI) and clinical AD [15]. The intent of the
current study is to validate the AQ as an accurate informant-
based instrument in detecting both MCI and clinical AD.
Methods
Study sample
Three-hundred individuals were included in this study (100
CN, 100 MCI, 100 AD). The AD and MCI cases were
drawn from the practices of three physicians and were
between the ages of 56 and 93. The cognitively normal
(CN) cases were between the ages of 53 and 93 and were
recruited from a brain and body donation programme [16]
in which the AQ was administered as part of their annual as-
sessment. An exemption was granted for this study by the
institutional review board as it fell under the categorisation
of research involving the use of educational tests (cognitive,
diagnostic, aptitude, achievement), survey procedures, inter-
view procedures or observation of public behaviour.
The AD cases met NINCDS-ADRDA [17] criteria for a
clinical diagnosis of probable or possible Alzheimer’s disease.
MCI cases were diagnosed as such based on Petersen criteria
[18]. These criteria require the presence of subjective
memory complaints and objective memory test performance
that falls 1.5 standard deviations below age- and education-
corrected mean values. Both single and multiple domain
amnestic MCI cases were included. The CN cases were
deﬁned as having a global CDR score of 0 and were not
impaired in any cognitive domain measured by neuropsycho-
logical testing. Individuals with MMSE scores below 20 were
excluded so that the data better reﬂected a population seen in
a primary care setting for cognitive complaints.
Consensus diagnosis with a neurologist, geriatric psych-
iatrist and neuropsychologist was used to determine the clin-
ical status of CN individuals. Consensus diagnoses were
made based on neuropsychological testing, neurological and
physical exam and interviews with an informant, which
assessed global cognitive status, functional status and mood
and behavourial status. Clinician’s diagnosis consisting of
medical history, social history, neuroimaging, clinical labora-
tory results and neuropsychological testing was used for
MCI and AD individuals. Individuals with any type of brain-
related neurological or psychiatric illness were excluded.
The Alzheimer’s questionnaire
The AQ [15] is a 21-item, informant-based dementia as-
sessment. AQ items are divided into ﬁve domains including
Memory, Orientation, Functional Ability, Visuospatial and
Language. Items are posed in a yes/no format with the
sum of points for ‘yes’ items equaling the total score that
ranges from 0 to 27 with higher scores corresponding to
greater impairment. Six items known to be predictive of a
clinical AD diagnosis are weighted more heavily in the total
score by being worth two points rather than one (please
see Supplementary data available in Age and Ageing online,
Appendix 1). The AQ was administered by a neurologist,
geriatric psychiatrist and also by psychometrists trained by
the neurologist and geriatric psychiatrist.
Items for the AQ are based on those from other
informant-based assessments [11–14]. and were selected by
a group of clinicians with extensive experience in dementia
assessment. The items were selected based on their face
validity to assess each of the AQ domains. Six items were
selected to be weighted in the AQ total score as it was
agreed that these items would clearly differentiate an
impaired individual from a CN individual.
Statistical analysis
One-way analysis of variance (ANOVA) was used to
discern group differences on age, education, MMSE score
and AQ total score. Receiver-operating characteristic (ROC)
analysis was used to determine sensitivity, speciﬁcity, area
under the curve (AUC), likelihood ratios and cut-off scores
for MCI and AD. Correlations between the mean domain
scores were derived in order to assess internal consistency
along with Cronbach’s alpha. Analysis of covariance
(ANCOVA) was used to compare group differences on the
AQ total score while using age, education and gender as
covariates in order to account for their effects. Bonferroni
adjustment was used to correct for multiple comparisons.
Results
Demographic characteristics are displayed in Table 1.
One-way ANOVA yielded statistically signiﬁcant effects for
age, education, MMSE score and AQ total score between
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Demographic characteristics of study sample with
mean MMSE and AQ scores
CN MCI AD Total P-value
n 100 100 100 300 —
Age 77.98 (7.11) 74.82 (7.58) 78.17 (7.23) 76.99 (7.45) 0.002
Education 15.46 (2.89) 14.53 (2.50) 14.50 (2.48) 14.83 (2.63) 0.01
Gender (M/F) 38/62 60/40 59/41 157/143 0.002
MMSE 28.62 (1.44) 26.85 (2.50) 24.15 (2.51) 26.54 (2.76) <0.001
AQ score 2.44 (2.54) 11.23 (4.80) 17.74 (4.78) 10.47 (7.53) <0.001
CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer’s
disease, Mean (SD); MMSE normal range (26–30), AQ normal range (0–4).
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the clinical groups. An additional one-way ANOVA found a
statistically signiﬁcant difference for gender on the AQ total
score. ANCOVA which adjusted for age, education and
gender was then used to analyse clinical group differences
on the AQ total score [F = 327.68, (df = 2, 294),
P< 0.001].
Sensitivity, speciﬁcity, AUC, likelihood ratios (positive
and negative) and cut-off scores for the AQ total score are
displayed in Table 2. Two ROC analyses were carried out in
order to derive AUC values. The ﬁrst analysis used MCI as
the outcome and CN as the reference while the other used
AD as the outcome and CN as the reference. An additional
ROC analysis was run with AD as the outcome and MCI
as the reference in order to determine cut-off scores across
a continuum. These analyses yielded high sensitivity and
speciﬁcity for both MCI and AD.
Internal consistency was high (Cronbach’s α= 0.89).
Correlations among the domain scores were moderate
ranging from r = 0.45 to r= 0.69 (please see Supplementary
data available in Age and Ageing online, Table S4).
Discussion
The results of this study show that the AQ is a valid
measure of cognitive status and accurately identiﬁes indivi-
duals with AD and MCI. In addition, the AQ requires ap-
proximately 3 min to administer and is easily interpreted.
The rationale for weighting certain items on the AQ is that
they reﬂect the presence of cognitive symptoms which are
highly predictive of the clinical AD diagnosis [19]. Given
that subjective memory complaints are common among
older adults [20] using weighted items may assist in more
accurately identifying individuals who are impaired. The
AQ is not intended to replace a full diagnostic work-up
that is done when assessing cognitive problems. It is
intended to be a screening instrument used to determine
which individuals require further evaluation.
The data for this study came from patients who were
seen by dementia specialists so these results may not repre-
sent the general geriatric population. Another problem is
that the AQ requires the use of an informant. In many
cases, individuals may see a clinician by themselves or may
not have a reliable informant. Additionally, the study
sample was ethnically homogenous as the majority of parti-
cipants were Caucasian. One other problem is that the clin-
ical groups were very speciﬁc and did not include other
diagnostic groups, such as vascular or frontotemporal de-
mentia. In addition, MCI is a heterogeneous condition that
can occur from multiple aetiologies and does not necessar-
ily progress to clinical AD. Therefore, screening for this
clinical entity can be problematic if other medical and
social information is utilised. However, given recent interest
in MCI as treatable not entity [21], instruments that identify
individuals early in the disease process may help lead to
better outcomes.
Overall, the AQ may be a useful tool to clinicians who
require the use of a brief and accurate cognitive assessment.
As mandates for cognitive screening among older adults
are implemented [2], the AQ would ﬁll the need for a brief
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Informant-reported cognitive symptoms that
predict amnestic mild cognitive impairment
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Abstract
Background: Differentiating amnestic mild cognitive impairment (aMCI) from normal cognition is difficult in
clinical settings. Self-reported and informant-reported memory complaints occur often in both clinical groups,
which then necessitates the use of a comprehensive neuropsychological examination to make a differential
diagnosis. However, the ability to identify cognitive symptoms that are predictive of aMCI through informant-based
information may provide some clinical utility in accurately identifying individuals who are at risk for developing
Alzheimer’s disease (AD).
Methods: The current study utilized a case-control design using data from an ongoing validation study of the
Alzheimer’s Questionnaire (AQ), an informant-based dementia assessment. Data from 51 cognitively normal (CN)
individuals participating in a brain donation program and 47 aMCI individuals seen in a neurology practice at the
same institute were analyzed to determine which AQ items differentiated aMCI from CN individuals.
Results: Forward stepwise multiple logistic regression analysis which controlled for age and education showed
that 4 AQ items were strong indicators of aMCI which included: repetition of statements and/or questions [OR
13.20 (3.02, 57.66)]; trouble knowing the day, date, month, year, and time [OR 17.97 (2.63, 122.77)]; difficulty
managing finances [OR 11.60 (2.10, 63.99)]; and decreased sense of direction [OR 5.84 (1.09, 31.30)].
Conclusions: Overall, these data indicate that certain informant-reported cognitive symptoms may help clinicians
differentiate individuals with aMCI from those with normal cognition. Items pertaining to repetition of statements,
orientation, ability to manage finances, and visuospatial disorientation had high discriminatory power.
Background
The process of differentiating age-associated memory
decline from those who might have a clinically signifi-
cant disorder of memory and cognition is difficult. In
particular, distinguishing individuals with amnestic mild
cognitive impairment (aMCI) from those who are cogni-
tively normal (CN) is challenging, as memory and cogni-
tive complaints are often reported in both groups from
both the patient and informants [1]. Given that the cur-
rent diagnostic criteria for aMCI include subjective
(patient and/or family report of decline) and objective
(neuropsychological testing) evidence of memory
decline, a clinician’s initial impression from a relatively
short office visit may not allow for an accurate assess-
ment [2].
Amnestic MCI was first characterized as a syndrome
consisting of memory performance at or below 1.5 stan-
dard deviations (SD) on age- and education-adjusted
normative values on a verbal memory test along with
subjective memory complaints, preserved global cogni-
tion, and preserved activities of daily living [3]. The
diagnostic criteria for MCI have since been refined to
differentiate between amnestic and non-amnestic forms,
with the latter showing performance at or below 1.5 SD
on a test or test(s) in one or more domains other than
memory. Both amnestic and non-amnestic MCI can be
further classified as single or multiple domain MCI
depending upon the number of cognitive domains that
show test performance(s) at or below 1.5 SD [4].
Several studies have investigated the clinical course
and presentation of individuals who have self- and infor-
mant-reported memory complaints [5-8]. Some evidence
suggests that individuals who are cognitively normal and
have subjective memory complaints demonstrate MRI
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findings that are similar to those of aMCI individuals
[9]. Other studies have demonstrated that an infor-
mant’s report of an individual’s cognitive status is valid
and highly accurate in the very early stages of AD [6].
Although the diagnostic criteria for aMCI do not
include functional impairment, previous studies have
found that aMCI patients may have difficulty with
higher level daily activities, such as balancing a check-
book, and may show mild, but not significant, difficulty
in daily functioning [1,10].
Utilizing additional information with added discrimi-
natory power can aid in identifying individuals at risk
for developing Alzheimer’s disease (AD), a task of
greater interest now, with emerging early AD treatments
[10,11]. To accomplish this, identifying certain cognitive
symptoms that may yield greater diagnostic accuracy
than subjective memory complaints alone is necessary.
A recent pilot study found that the Alzheimer’s Ques-
tionnaire (AQ), an informant-based questionnaire
designed for use in primary care settings, has both high
sensitivity [87.00 (77.00 - 94.00)] and specificity [94.00
(84.00, 99.00)] for aMCI [12].
The intent of this study is to determine which AQ
items are predictive of aMCI. By identifying cognitive
symptoms beyond subjective memory complaints, indivi-
duals at risk for developing AD may be identified more
quickly so that further diagnostic testing and subsequent
treatment may be initiated sooner in the disease process.
Method
Study Sample
Data from 98 individuals (47 aMCI, 51 CN) were taken
from an ongoing validation study of the AQ. Both aMCI
and CN individuals were drawn from the same geo-
graphic population (Sun City, AZ). A case-control
design was used for this study as the aMCI participants
were drawn from the practice of a neurologist specializ-
ing in dementia and memory disorders. The clinician’s
diagnosis was used as the gold standard for aMCI parti-
cipants, based on cognitive and medical history, infor-
mant interview, and neuropsychological testing utilizing
Petersen criteria [3]. Individuals whose performance was
1.5 standard deviations (SD) below age- and education-
corrected means on a delayed recall measure of verbal
memory were classified as aMCI. Individuals with both
single and multiple domain aMCI were included in the
analysis. Multiple domain aMCI cases were classified as
those with memory performance 1.5 SD below age- and
education-corrected means with performance in another
cognitive domain (e.g., executive functions) also falling
1.5 SD below age- and education-corrected means.
CN participants were drawn from a brain and body
donation program in which informants were given the AQ
as part of the participants’ annual assessment. Both aMCI
and CN participants were recruited consecutively. CN par-
ticipants were defined as having no demonstrable cogni-
tively-based limitations of activities of daily living through
an informant interview by a physician. In addition, all CN
participants scored above 1.5 SD on age- and education-
corrected means on a battery of neuropsychological tests
and received global CDR rating of 0 [13]. Consensus diag-
nosis with a neurologist, geriatric psychiatrist, and neurop-
sychologist was used as the gold standard in determining
CN status. The AQ was not utilized in the differential
diagnosis for aMCI individuals and was not utilized in the
consensus diagnosis for CN individuals. Interviews with
the participant and informant and review of medical
records were used to exclude those with symptomatic or
severe brain-related neurological or psychiatric illness.
Excluded conditions included mental retardation, epilepsy,
cerebral infarction or hemorrhage, multiple sclerosis, brain
tumor, major depressive disorder (unipolar or bipolar),
schizophrenia, traumatic brain injury, and substance
abuse. Collateral informants provided additional informa-
tion on cognitive and functional changes.
IRB approval was waived by the Sun Health IRB as the
study fell under their categorization of research invol-
ving the use of educational tests (cognitive, diagnostic,
aptitude, achievement), survey procedures, interview
procedures or observation of public behavior which is
not subject to review and does not require informed
consent. None of the authors on this paper served on
the Sun Health IRB and the granting bodies that pro-
vided funding for this study did not require any type of
ethics review.
Neuropsychological Tests
Rey Auditory Verbal Learning Test [14]
A list of 15 words is read aloud to the individual after
which they are asked to recall as many words as possible
in any order. This is done 5 times. After the fifth trial, a
new 15-word list is read aloud to the individual after
which they are asked to recall as many words as possible
in any order. They are then asked to recall the words
they remember from the list that was read to them 5
times. After a 20 minute delay, they are again asked to
recall words from the list that was read 5 times.
WMS-R Logical Memory [15]
A short fictional story is read to the individual after
which they are asked to repeat as much of the story as
they can remember. After a 20 minute delay, they are
asked to recall the story again.
Trails A [16]
The individual is instructed to draw a line that connects
circled numbers in consecutive order.
Trails B [16]
The individual is asked to draw a line that connects
circled numbers and circled letters in consecutive order
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while alternating between numbers and letters (1 - A - 2
- B - 3 - C, etc).
Controlled Oral Word Association Test [14]
Individuals are given one minute to verbally produce as
many words as they can that begin a given letter. One
minute per word is given.
Animal Fluency [14]
Individuals are given one minute to verbally produce as
many names of animals as they can.
Stroop Color/Word [17]
The individual is presented with 5 columns of the words
“blue”, “red”, and “green” presented in random order.
The words are printed in an ink that is incongruent
with the actual word itself (ie, the word “blue” is printed
in red ink). The individual is then asked to identify the
color of the ink the word is printed in. There is a 45-
second time limit in which the individual must give as
many correct responses as possible.
Judgment of Line Orientation [18]
Individuals are asked to match a set of two lines set at
varying angles and lengths to a reference of lines placed
below each stimulus card for each trial.
The Alzheimer’s Questionnaire (AQ)
The Alzheimer’s Questionnaire (AQ) is a 21-item, infor-
mant-based dementia assessment designed for ease of
use in a primary care setting. AQ items are divided into
five domains including Memory, Orientation, Functional
Ability, Visuospatial Ability, and Language. Items are
posed in a yes/no format with the sum of ‘yes’ items
equaling the total AQ score (0-27). Six items known to
be predictive of a clinical AD diagnosis are weighted
more heavily in the total score by being worth two
points rather than one.
Statistical Analysis
Data from the individual AQ items were first analyzed
using the Chi-square statistic to determine if there were
significant differences in positive response frequencies
between aMCI and CN individuals for each item. Multi-
ple forward stepwise logistic regression was carried out
to determine the predictive ability of individual AQ items
while adjusting for the effects of age and education. For
this analysis, clinical status (aMCI) was the outcome and
the individual AQ items were entered as predictors. Cri-
teria for retaining predictor variables was set to alpha <
.05. Nagelkerke’s R2 was used to determine the amount
of variance accounted for by the logistic model.
Systat 13.0 was used to carry out all analyses.
Results
Demographic characteristics of the study sample are dis-
played in Table 1. The CN group was older and slightly
more educated than the aMCI group. Males and females
had relatively equal representation across groups. Chi-
square analysis showed significant differences in
response frequencies for all but two AQ items (Table 2).
Results from the multiple forward stepwise logistic
regression analysis, which adjusted for age and educa-
tion, are displayed in Table 3; only the AQ items that
were included in the stepwise model are shown. This
model yielded four AQ items as strong predictors of
aMCI, which are listed in Table 3 with their associated
odds ratios (OR), 95% confidence intervals, and p-values.
The resulting stepwise logistic model yielded a Nagelk-
erke R2 of 0.71 indicating that a large proportion of the
variance between aMCI and CN individuals was
accounted for by the four AQ items.
In order to more accurately characterize the clinical
validity of these findings, a second non-stepwise logistic
regression analysis was carried out which used only the
four significant AQ items while correcting for age and
education. This model yielded sensitivity of 80.30 (67.00,
89.53) and specificity of 81.80 (69.67, 90.37) with an
area under the curve (AUC) value of 0.94 (0.89, 0.99).
Discussion and Conclusions
The results of the study indicate that the four infor-
mant-reported items listed immediately above are highly
predictive of aMCI. These items are memory-related,
and also suggest some degree of impairment in higher-
level functional abilities. The use of informant-supplied
information is a widely-used and highly valid method of
assessing an individual’s cognitive and functional abil-
ities [5,7]. Relative to other informant-based instruments
[19-22] the AQ takes substantially less time to adminis-
ter [12], a fact of importance to clinicians with very lim-
ited time [23].
For clinicians who see patients with subjective mem-
ory complaints, accurate identification of those who
need further evaluation is critical to cost containment
and resource management. A significant proportion of
older adults present with subjective memory complaints
[24,25], and these complaints can precede the onset of
clinical AD [26]. The large and growing number of
older adults underscores the importance of utilizing
brief and accurate screening measures. Additionally, as
Table 1 Demographic Characteristics
CN aMCI Total
N 51 47 98
Male (%) 43 57 50
Female (%) 57 43 50
Age 78.59 (6.72) 74.36 (7.19) 76.56 (7.23)
Education 15.04 (3.03) 14.43 (2.51) 14.74 (2.79)
MMSE 28.47 (1.27) 26.89 (1.90) 27.71 (1.78)
Mean (sd)
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new therapies for AD transition from being sympto-
matic to disease-modifying, identifying individuals who
are at-risk or are in the earliest stages of the disease will
be crucial in determining and improving disease out-
come [1].
There are some limitations to this study. The first is
that the confidence intervals for the odds ratios of the
statistically significant AQ items were relatively wide,
indicating decreased statistical power. Although the
sample was large enough to yield robust odds ratios for
the four AQ items, a larger sample size might provide a
more accurate estimate of effect size. In addition, the R2
value may not truly represent the amount of variance
accounted for by the model. The reason for this is that
R2 values in logistic models are approximations of lin-
ear-based R2 measures and are not fully equivalent. In
addition, R2 measures used in logistic models are prone
to bias when used with small sample sizes and may







Does the patient have memory loss? 25.99 <
.0001
46/47 27/51
If so, is their memory worse than a few years ago? 6.30 .01 33/47 23/51
Does the patient repeat questions or statements or stories in the same day? 37.60 <
.0001
33/47 5/51
Have you had to take over tracking events or appointments, or does the patient forget appointments? 21.77 <
.0001
30/47 9/51
Does the patient misplace items more than once a month, or does the patient misplace objects so that he/she
cannot find them?
11.95 .005 33/47 18/51
Does the patient suspect others of moving, hiding, or stealing items when he/she cannot find them? 3.53 .06 7/47 2/51
Does the patient frequently have trouble knowing the day, date, month, year, and time; or does the patient




Does the patient become disoriented in unfamiliar places? 17.78 <
.0001
24/47 6/51
Does the patient become more confused when travelling outside the home? 9.87 .0017 21/47 8/51
Excluding physical limitations, does the patient have trouble handling money (tips, calculating change)? 5.72 .02* 5/47 0/51
Excluding physical limitations, does the patient have trouble paying bills or doing finances; or are family members




Does the patient have trouble remembering to take medications or tracking medications taken? 16.76 <
.0001
19/47 3/51
Is the patient having difficulty driving; or are you concerned about the patient’s driving; or has the patient stopped
driving for reasons other than physical limitations?
0.50 .48 11/47 9/51
Is the patient having trouble using appliances? 4.31 .05* 6/47 1/51
Excluding physical limitations, is the patient having difficulty in completing home repair or housekeeping tasks? 9.16 .003 10/47 1/51
Is the patient getting lost in familiar surroundings? 4.31 .04 6/47 1/51
Does the patient have a decreased sense of direction? 19.99 <
.0001
24/47 5/51
Does the patient have trouble finding words other than names? 6.81 .009 24/47 13/51
Does the patient confuse names of family members or friends? 15.94 <
.0001
20/47 4/51
Does the patient have difficulty recognizing people familiar to him/her? 6.94 .009 6/47 0/51
* Fisher’s exact test p-value was used due to expected cell counts less than 5





Does the patient repeat questions or




Does the patient frequently have trouble knowing the day, date, month, year, and time; or does the patient reference




Excluding physical limitations, does the patient have trouble paying bills or doing finances; or are family members




Does the patient have a decreased sense of direction? 5.84 (1.09,
32.30)
0.04
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result in an inflated estimate of the amount of variance
accounted for [27]. Another limitation is that the AQ
itself requires the use of an informant. In some cases, a
patient may come to a physician’s office alone or they
may not have a reliable informant available to do the
assessment. Although several patient-based cognitive
assessments, such as the Mini Mental State Exam [28],
can be used, they are subject to confounding factors
such as cultural effects and low education [29-31].
Finally, the study sample was homogenous with respect
to ethnicity, as all subjects were Caucasian, so it is
unclear whether these results are applicable to an ethni-
cally diverse population.
In addition, the ability of other widely-used informant-
based instruments to accurately identify clinical aMCI
has not been established. The validity and accuracy of
the AD8 has been established in clinical AD and in indi-
viduals with a CDR global rating 0.5 which is considered
“very mild dementia” [32]. It is important to note that
this categorization (CDR = 0.5) does not necessarily
equate to a clinical diagnosis of aMCI so it is uncertain
whether the AD8 can accurately identify clinically-
defined aMCI cases. In addition, a recent study demon-
strated that the IQCODE does not have high sensitivity
in the detection of aMCI [33]. As mentioned earlier, a
previous pilot study of the AQ demonstrated high sensi-
tivity and specificity for aMCI when compared to cogni-
tively normal individuals. The results of the current
study showed that four statistically significant AQ items
accounted for large proportion of the variance between
aMCI and CN individuals and also yielded high sensitiv-
ity and specificity in differentiating the two groups.
Overall, the results of this study indicate that certain
AQ items can differentiate individuals with aMCI from
those experiencing age-associated changes in memory
and cognition. As assessed by the AQ, difficulties with
orientation to time, repetition of questions and state-
ments, difficulties in managing finances, and visuospatial
disorientation were all significant predictors of aMCI as
diagnosed by an expert in memory disorders.
Given that memory complaints are commonly
reported by elderly patients and their family members
[7], a means to quickly and accurately identify indivi-
duals who may be in the early stages of AD and in need
of further evaluation is critical to not only cost contain-
ment and resource management, but also to earlier diag-
nosis in order to improve disease outcome. These data
indicate that problems with orientation to time, repeat-
ing statements and questions, difficulty managing
finances, and trouble with visusospatial orientation may
accompany memory deficits in aMCI. From a clinical
standpoint, these findings are important as it will allow
clinicians to more easily and accurately determine which
individuals require further assessment of cognitive
problems.
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Comparative Analysis of the Alzheimer Questionnaire (AQ)
With the CDR Sum of Boxes, MoCA, and MMSE
Michael Malek-Ahmadi, MSPH, Kathryn Davis, BA, Christine M. Belden, PsyD,
and Marwan N. Sabbagh, MD
Abstract: The Alzheimer Questionnaire (AQ) has been established
as a valid and accurate informant-based screening questionnaire
for Alzheimer disease and amnestic mild cognitive impairment.
Although the AQ’s validity and diagnostic accuracy has been
established, its performance in comparison with other instruments
has not. Thirty-nine amnestic mild cognitive impairment cases and
34 Alzheimer disease cases were matched on the basis of age,
education, and sex to 73 cognitively normal individuals. The
sample had a mean age of 82.54±7.77 years and a mean education
level of 14.61±2.61 years. The diagnostic accuracy of the CDR
Sum of Boxes, Mini Mental State Exam (MMSE), and Montreal
Cognitive Assessment (MoCA) were compared with the AQ. The
AQ correlated strongly with the CDR Sum of Boxes (r=0.79) and
demonstrated similar diagnostic accuracy with the MoCA and
MMSE. These results suggest that the AQ is comparable with other
established informant-based and patient-based measures.
Key Words: cognitive screening, mild cognitive impairment, neuro-
psychological tests, dementia screening
(Alzheimer Dis Assoc Disord 2012;00:000–000)
The Alzheimer Questionnaire (AQ) has been establishedas a valid and accurate informant-based screening
questionnaire for both Alzheimer disease (AD) and
amnestic mild cognitive impairment (aMCI).1 It is similar in
content and structure to other informant-based dementia
screening questionnaires,2,3 but contains questions that
probe several domains including memory, orientation,
functional ability, visuospatial function, and language.
Given the widespread use of measures such as the Clinical
Dementia Rating (CDR),4 Mini Mental State Exam
(MMSE),5 and the Montreal Cognitive Assessment
(MoCA),6 comparing the AQ’s performance to them is
important to further establish its validity. As the AQ is
purely an informant-based instrument, comparing it to
patient-based assessments (MoCA and MMSE) and with
the CDR, which uses both informant-based and patient-
based information, a broader assessment of the AQ’s val-
idity can be made from these comparisons.
METHODS
Study Sample
Data from 146 individuals participating in a brain and
body donation program7 were used for this study. Partic-
ipants in this program are recruited predominantly from the
northwest region of the Phoenix, Arizona metropolitan
area. Informed consent was obtained from all individuals
before enrolling in the program. The age of the participants
for this study ranged from 57 to 97 years with a mean of
82.54±7.77 years and had a mean education level of
14.61±2.61 years and included 82 females and 64 males.
Of the 146 individuals, 73 were classiﬁed as cognitively
normal (CN), 39 as aMCI, and 34 as AD. Demographic
characteristics of the clinical groups are reported in Table 1.
Each aMCI and AD individual was matched on the basis of
age, education, and sex to a CN individual. Both single and
multiple domain aMCI cases were categorized as aMCI and
both possible and probable AD were categorized as AD.
The AD cases met NINCDS-ADRDA8 criteria for a clin-
ical diagnosis of probable or possible AD. The aMCI cases
were diagnosed as such based on Petersen criteria.9 The CN
cases were deﬁned as having no limitations of activities of
daily living by informant report and were within normal
limits on neuropsychological testing.
Consensus diagnosis with a neurologist, geriatric psy-
chiatrist, and neuropsychologist was used to determine the
clinical status of each individual. Consensus diagnoses were
made based on neuropsychological testing results, neuro-
logical and physical examination, and interviews with an
informant that assessed global cognitive status, functional
status, and mood and behavioral status. The AQ was not
used in making the consensus diagnosis.
Statistical Analysis
Diagnostic accuracy of the individual tests was
assessed using ROC analysis through the use of area under
the curve (AUC) values. The Shapiro-Wilk test was per-
formed on the data to determine the normality of dis-
tribution for the continuous variables. Nonparametric tests
for group comparisons and correlations were used as the
data for all continuous variables were not normally dis-
tributed. The Kruskall-Wallis test was used to compare the
AQ total score among participants when grouped by both
clinical status (CN, aMCI, AD) and CDR Global Score (0;
0.5; 1, 2, 3). The Conover-Inman test was used to assess
groupwise diﬀerences for the Kruskall-Wallis tests. A
Bonferroni-adjusted P-value of 0.02 was used to determine
statistical signiﬁcance for the clinical group and CDR
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Global Score group comparisons. Cohen’s d was used to
assess the eﬀect size for each group comparison. Spearman
correlation analysis was used to determine the degree of
association between the AQ, CDR-SOB, MoCA, and
MMSE. A false discovery rate10 P-value of 0.008 was used
to correct for multiple comparisons among the correlations.
Statistical analyses were carried out using Systat 12.0
(Systat Inc., Chicago, IL) and MedCalc 12.2 (MedCalc
Software, Mariakerke, Belgium).
RESULTS
The Shapiro-Wilk test found that age, education, AQ,
MoCA, MMSE, and CDR-SOB were not normally dis-
tributed. The distribution of males and females between
clinical groups was not statistically signiﬁcant (w2=0.57,
df=2, P=0.75) (Table 1). There were no signiﬁcant dif-
ferences in age (Kruskall-Wallis=5.35, df=2, P=0.07)
or education level (Kruskall-Wallis=0.54, df=2,
P=0.76) between the clinical groups (Table 1).
Table 2 shows the AUC values with 95% conﬁdence
intervals for each of the instruments for all clinical groups.
The AQ, MoCA, and MMSE demonstrated comparable
AUC values for both aMCI and AD, whereas the CDR-
SOB demonstrated greater discriminatory power for aMCI
than the other instruments. Groupwise comparisons from
the Kruskall-Wallis test demonstrated that all 3 clinical
groups were signiﬁcantly diﬀerent from each other on AQ
total score (Kruskall-Wallis=79.55, df=2, P<0.001; all
groupwise comparisons P<0.001). Eﬀect sizes (Cohen’s d)
for AQ clinical group diﬀerences were as follows: CN ver-
sus aMCI=0.98, CN versus AD=3.51, aMCI versus
AD=2.04. The AQ correlated strongly with the CDR-
SOB (r=0.79) and correlated moderately with the MMSE
(r= 0.56) and MoCA (r= 0.46). The MoCA was
moderately correlated with the MMSE (r=0.63) and
CDR-SOB (r= 0.62). The MMSE and CDR-SOB were
strongly correlated (r= 0.76). All correlations yielded
P-values that were P<0.001.
An additional analysis was carried out to characterize
the AQ’s performance when participants were grouped
according to their Global Score on the CDR [CDR 0
(n=66); CDR 0.5 (n=49); CDR 1, 2, 3 (n=31)]. Indi-
viduals with a CDR Global Score of 1, 2, and 3 were
combined as these 3 subgroups were not signiﬁcantly dif-
ferent from each other when compared separately on the
AQ total score. A statistically signiﬁcant diﬀerence for the
AQ total score was noted between the 3 CDR Global Score
groups (Kruskall-Wallis=82.35, df=2, P<0.001; all
groupwise comparisons P<0.001). Cohen’s d was used
to assess the eﬀect sizes of these group diﬀerences and
found the following: CDR 0 versus CDR 0.5=1.27;
CDR 0 versus CDR 1, 2, 3=3.70; CDR 0.5 versus CDR 1,
2, 3=1.87.
DISCUSSION
This study demonstrated that the AQ is comparable
with other commonly used informant-based and patient-
based measures in terms of its ability to diﬀerentiate aMCI
and AD patients from those who are CN. When the study
sample was grouped according to the CDR Global Score,
there were very large diﬀerences between the dementia
(AD), questionable dementia (aMCI), and no dementia
(CN) groups on the AQ total score.
The AQ’s AUC value for aMCI was much lower than
previously reported,1 which is likely due to the smaller
sample size of the current study. The validation study of the
AQ1 used a larger sample (100 CN, 100 aMCI, and 100
AD); however, its ability to diﬀerentiate aMCI in this study
was similar to the MMSE and MoCA. The CDR-SOB
yielded a higher AUC than the AQ, but this is likely
because the CDR-SOB was used to make the consensus
diagnoses, resulting in an inﬂated AUC value. Despite this
weakness, the inclusion of the CDR-SOB AUC value does
provide some frame of reference to compare with the other
instruments. The AQ correlated moderately with the
MMSE and MoCA, which is expected as the modalities of
instrument administration (patient-based vs. informant-
based) diﬀer greatly.
One weakness of the study is that the sample was
homogenous with respect to ethnicity as the majority of
participants in this study were white. Therefore, it is unclear
whether these results can be applied to a more ethnically
diverse population. Another weakness is the relatively small
sample size to assess diagnostic accuracy of the instruments
used in the study. Despite these shortcomings, this study
demonstrated that the AQ’s performance is comparable
with other widely-used informant-based and patient-based
instruments.
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Abstract. Informant-based assessments of cognition and function are commonly used to differentiate individuals with amnestic
mild cognitive impairment (aMCI) and Alzheimer’s disease (AD) from those who are cognitively normal. However, determining
the extent to which informant-based measures correlate to objective neuropsychological tests is important given the widespread
use of neuropsychological tests in making clinical diagnoses of aMCI and AD. The aim of the current study is to determine how
well the Alzheimer’s Questionnaire (AQ) correlates with objective neuropsychological tests. The study utilized data from 300
individuals participating in a brain and body donation program. Individuals diagnosed with aMCI (n = 83) and AD (n = 67) were
matched on age, gender, and education to a control individual (n = 150). The average age for the entire sample was 83.52 ± 6.51
years with an average education level of 14.57 ± 2.55 years. Results showed that the AQ correlated strongly with the Mini-Mental
State Exam (r = −0.71, p < 0.001) and the Mattis Dementia Rating Scale-2 (r = −0.72, p < 0.001), and moderate correlations
were noted for the AQ with memory function (Rey Auditory Verbal Learning Test Delayed Recall, r = −0.61, p < 0.001) and
executive function (Trails B, r = 0.53, p < 0.001). The findings of this study suggest that the AQ correlates well with several
neuropsychological tests and lend further support to the validity of the AQ as a screening instrument for cognitive impairment.
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INTRODUCTION
As the prevalence of Alzheimer’s disease (AD)
continues to increase [1], so too does the need for
a brief and accurate informant-based screening tool
for the detection of AD and amnestic mild cognitive
impairment (aMCI). Informant-based questionnaires
are commonly used in both clinical and research set-
tings for the purpose of differentiating aMCI and AD
individuals from those who are cognitively normal
(CN) [2, 3]. The Informant Questionnaire on Cog-
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nitive Decline in the Elderly (IQCODE) and AD8
have demonstrated good diagnostic accuracy for AD
and have been found to correlate well with other
conventional cognitive screening tests, such as the
Mini-Mental State Examination (MMSE) [4, 5]. How-
ever, these measures may not accurately identify aMCI
individuals.
The Alzheimer’s Questionnaire (AQ) is a 21-item,
informant-based assessment designed for ease of use
in the clinical setting that has demonstrated high sen-
sitivity and specificity for both aMCI and AD [6, 7].
The concurrent validity of the AQ with other estab-
lished measures of cognition was demonstrated by
Malek-Ahmadi et al. [8] who found that the AQ cor-
relates strongly with the Clinical Dementia Rating
Sum of Boxes (r = 0.79) and moderately with the
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MMSE (r = −0.56) and Montreal Cognitive Assess-
ment (MoCA) (r = −0.46).
Although the diagnostic accuracy and concurrent
validity of the AQ have been established [6–8], the
degree to which the AQ is associated with neuropsy-
chological and cognitive screening tests has not been
investigated. Since neuropsychological tests are uti-
lized in making clinical diagnoses of aMCI and AD,
determining the extent to which the AQ correlates with
objective and specific measures of various cognitive
domains is needed in order further validate its abil-
ity to detect cognitive changes associate with aMCI
and AD. This study will determine the extent to which
the AQ correlates with performance-based neuropsy-
chological tests commonly used in clinical settings, as




Data from 300 individuals participating in the Ban-
ner Sun Health Research Institute (BSHRI) Brain and
Body Donation Program were utilized for this study
[9]. Participants in this program are recruited pre-
dominantly from the northwest region of the Phoenix,
Arizona metropolitan area and are recruited from a
variety of sources (clinic referral, community adver-
tisement, talks in the community given by clinicians,
word-of-mouth referral from current participants).
Written informed consent, approved by the (BSHRI)
Institutional Review Board, was obtained from all sub-
jects. Each subject with aMCI or AD was matched on
age, education, and gender to a CN individual, without
replacement. When an exact match could not be found,
a tolerance of ± 2 years was used for age and education
in order to obtain an approximate match.
Both single and multiple domain aMCI cases were
categorized as aMCI. Amnestic MCI cases were diag-
nosed using Petersen criteria [10] and were considered
to be aMCI due to AD. The AD cases met NINCDS-
ADRDA criteria for a clinical diagnosis of probable or
possible AD [11]. The CN cases were defined as having
no limitations of activities of daily living by informant
report, were within normal limits on neuropsycholog-
ical testing, and did not receive a clinical diagnosis of
any cognitive disorder. Informants for all individuals
were a spouse/significant other, a child, or a friend with
frequent and close contact to the individual.
Consensus diagnoses were made by the study
physician and neuropsychologist based on neuropsy-
chological testing results, neurological and physical
exam findings, and interviews with the subject and
an informant that assessed global cognition, func-
tional status, and mood and behavioral status. The AQ
was not utilized in making the consensus diagnoses
and is utilized as a measure independent of diagnosis
for research purposes. The AQ was administered and
scored in a manner that was blinded from neuropsy-
chological assessments in order to avoid bias.
Instruments
Alzheimer’s questionnaire [7]
The AQ is a 21-item, informant-based dementia
screening assessment designed for ease of use in a
primary care setting. AQ items are divided into the
following five domains: Memory, Orientation, Func-
tional Ability, Visuospatial Ability, and Language.
Items are posed in a yes/no format with the count of
‘yes’ responses equaling the total AQ score (0–27). For
the AQ, higher scores indicate greater impairment. Six
items known to be predictive of a clinical AD diagno-
sis are weighted more heavily and are worth two points
each.
Mini-mental state examination [12]
The MMSE is a brief, 30-point cognitive screening
instrument that includes items measuring Orienta-
tion, Memory, Language, Attention, and Visuospatial
functions.
Montreal cognitive assessment [13]
The MoCA is a brief, 30-point cognitive screening
instrument that assesses cognitive domains includ-
ing Attention and Concentration, Executive Functions,
Memory, Language, Visuoconstructional Skills, Con-
ceptual Thinking, Calculations, and Orientation.
Mattis dementia rating scale-2 (DRS-2) [14]
The DRS-2 is a widely-utilized, structured assess-
ment of cognitive function. The instrument has five
subscales: Attention, Initiation/Perseveration, Con-
struction, Conceptualization, and Memory, with the
subscales used to derive a total score. For this study,
only the total score was used for the analyses.
Clock drawing test [15]
For this test, individuals are given a blank sheet of
paper and asked to draw the face of a clock and to set the
time to ten past eleven. A 10-point scoring system [15]
was used which is based on three components: Integrity
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of Numbers (0–4 points), Presence and Placement of
Hands (0–4 points).
Rey auditory verbal learning test (AVLT) [16]
A list of 15 words is read aloud to the individual, after
which they are asked to recall as many words as possi-
ble in any order, for a total of 5 repeated trials. After the
fifth trial, a new, distractor, 15-word list is read aloud to
the individual, from which they recall as many words
as possible. They are asked to recall the words they
remember from the initial list after the distractor list
and once more after a 20-minute delay. AVLT Total
is the sum of the number of correctly recalled words
for Trials 1–5. AVLT Delayed Recall is the number of
correct words recalled after a 20-minute delay.
Brief visuospatial memory test-revised
(BVMT-R) [17]
The BVMT-R is a test of visuospatial memory in
which subjects are presented with a page containing
six unique designs for 10 seconds. After the 10-second
presentation, subjects are asked to draw the shapes on
a blank page. Three such 10-second learning trials are
administered, and after a delay of 20 to 25 minutes, sub-
jects are asked to draw the shapes again on a blank page.
BVMT-R Total Score is the sum of points from the three
learning trials while the BVMT-R Delayed Recall is the
number of points from the delayed recall trial.
Trails A [18]
During this test, the individual is instructed to draw a
line that connects circled numbers in consecutive order.
Trails B [18]
The individual is asked to draw a line that connects
circled numbers and circled letters in consecutive order
while alternating between numbers and letters (1 – A –
2 – B – 3 – C, etc.).
Digit span forward [19]
Number sequences of increasing length are read
aloud to the participant, after which the number series
is repeated back to the examiner.
Digit span backward [19]
Number sequences are read aloud to the participant,
after which the number series is repeated back to the
examiner in reverse order.
Controlled oral word association test
(COWAT) [20]
Individuals are given one minute to say out loud as
many words as they can that begin with a specified
letter.
Animal ﬂuency [20]
For this test, individuals are given one minute to say
out loud as many names of animals as they can.
Stroop color/word [21]
The individual is presented with 5 columns of the
words “blue”, “red”, and “green” presented in random
order. The words are printed in an ink that is incongru-
ent with the actual word itself (e.g., the word “blue”
is printed in red ink). The individual is then asked to
identify the color of the ink of the printed word. There
is a 45-second time limit in which the individual must
give as many correct responses as possible.
Judgment of line orientation (JLO) [22]
Individuals are asked to match a set of two lines,
set at varying angles and lengths, to their respective
reference lines located below each stimulus card.
Block design [23]
Subjects manipulate a set of colored blocks to create
a design matching the stimulus design.
Boston naming test 30-item (BNT) [24]
The BNT consists of 30 line drawings of objects
shown individually to the subject, who is asked to name
the object.
Geriatric depression scale (GDS) [25]
The GDS is a 30-item depression screening ques-
tionnaire designed for older adults.
Statistical analysis
For the demographic variables, Chi-square analy-
sis was used to examine the distribution of males and
females among the three groups while the Kruskall-
Wallis test was used to determine whether age and
education differed significantly between groups. The
Shapiro-Wilk test was used to determine whether the
AQ and the individual neuropsychological variables
were normally distributed. Since the neuropsycholog-
ical variables and the AQ did not meet the assumption
of normality, Spearman correlation analyses were car-
ried out to assess the linear associations between the
AQ and the neuropsychological measures. Correlation
values were interpreted as weak (0.00–0.39), moder-
ate (0.40–0.69), or strong (0.70–1.00). Data for DRS-2
and Block Design were only available from smaller
subsets of the study sample (DRS-2, n = 79; Block
Design, n = 55). In order to minimize the impact of
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on neuropsychological tests, the CN, aMCI, and AD
groups were analyzed together. This also allowed for
the relationship between the AQ and the individual cog-
nitive tests to be assessed on a continuum of cognitive
impairment.
The percentage of variance accounted by each cog-
nitive test in AQ score was determined by using robust
least median of squares regression models with AQ
score as the outcome and cognitive test as the predic-
tor. Each test was modelled independently in order to
obtain a R2 value that was unique to each of the tests.
The additional predictive value of the AQ in aMCI
for a select subset of tests was assessed through a series
of logistic regression models. The first series of mod-
els used only the cognitive test score as predictor with
CN/aMCI as the outcome. A second series of models
included the AQ score along with the cognitive test.
Area under the curve (AUC) values between the first
and second models were compared in order to deter-
mine if the AQ added a significant amount diagnostic
accuracy when combined with a cognitive test. All
models included the GDS score in order to account
for the effect of depressive symptoms on cognitive
performance.
Statistical analyses were carried out using Systat
12.0 (Systat, Inc., San Jose, CA).
RESULTS
The sample for this study ranged in age from 67
to 99 years, with a mean of 83.52 ± 6.51 and a mean
educational level of 14.57 ± 2.55 years. The sample
included 163 females and 137 males. Of the 300 sub-
jects, 150 were classified as CN, 83 were classified
as aMCI, and 67 were classified as AD. Demographic
characteristics and results of the neuropsychological
tests for each of the clinical groups are reported in
Table 1. The groups were not significantly different
in terms of age (p = 0.99) or education (p = 0.33). The
Chi-square analysis indicated that there was no signifi-
cant difference in the distribution of males and females
among the three clinical groups (p = 0.90).
Correlations between the AQ and the individual cog-
nitive measures are shown in Table 2. Each cognitive
test was grouped according to its respective domain
of assessment (General Cognition: DRS-2, MoCA,
MMSE, Clock; Memory: AVLT and BVMT; Execu-
tive Function: Trails B, COWAT, Stroop Color/Word;
Language: BNT and Animal Fluency; Attention: Trails
A, Digit Span Forward, Digit Span Backward; Visu-
ospatial: JLO and Block Design).
The AQ correlated strongly with DRS-2 Total
(r = −0.72) and the MMSE (−0.71). The AQ showed a
Table 1
Demographic characteristics and neuropsychological data
CN aMCI AD Total p-value
n 150 83 67 300 –
Age 83.45 ± 6.49 83.59 ± 6.66 83.56 ± 6.44 83.52 ± 6.51 0.99
Education 14.57 ± 2.50 14.88 ± 2.62 14.18 ± 2.58 14.57 ± 2.55 0.33
Gender (M/F) 82/68 44/39 38/29 164/136 0.90
GDS 4 [1, 7] 3 [2, 7] 5 [2, 8] – 0.18
AQ 0 [0, 2] 10 [3, 13.75] 22 [19, 27] – –
MMSE 29 [27, 30] 27 [24, 28] 19 [14, 22] – –
MoCA 26 [24, 28] 21.50 [19, 23] 14 [9.75, 18.25] – –
DRS-2 140 [134, 141] 128 [126, 134] 102 [70, 123] – –
Clock Draw 10 [9, 10] 9 [8, 10] 8 [5, 9] – –
AVLT Total 40.50 [33, 50] 27 [21, 31] 19 [15, 23] – –
AVLT Delayed Recall 8 [5, 11] 2 [0, 3] 0 [0, 0] – –
BVMT-R Total 16 [11, 22] 8 [5, 10] 4 [1, 5.25] – –
BVMT-R Delayed Recall 7 [5, 9] 3 [1, 4] 0 [0, 1] – –
Trails B 93 [73, 123] 159 [119.25, 221] 300 [219, 300] – –
Stroop Color/Word 30 [23, 37] 21 [15.25, 29] 15 [8, 24.50] – –
COWAT 36 [31, 45] 29 [23, 39] 24 [15, 37.25] – –
Trails A 37 [30, 46.50] 52 [40, 62] 74.50 [55, 123] – –
Digit Span Forward 8 [6, 9] 8 [6, 9] 7 [5.25, 8] – –
Digit Span Backward 6 [5, 8] 5 [4, 6] 4 [3, 5] – –
BNT 27 [25, 28] 25 [23, 27] 21 [17, 23] – –
Animal Fluency 17 [14, 20] 13 [11, 16] 8 [6, 12] – –
Block Design 29 [24, 34] 26 [16, 32] 20 [16, 24] – –
JLO 24 [20, 27] 21 [18, 23.75] 20 [16, 24] – –
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Table 2
Correlation values for neuropsychological tests with the AQ
Domain Test Correlation with AQ p-value R2
General Cognition
MMSE −0.71 <0.001 0.63
MoCA −0.68 <0.001 0.57
DRS-2 −0.72 <0.001 0.71
Clock Draw −0.38 <0.001 0.31
Memory
AVLT Total −0.62 <0.001 0.44
AVLT Delayed Recall −0.61 <0.001 0.43
BVMT-R Total −0.61 <0.001 0.41
BVMT-R Delayed Recall −0.65 <0.001 0.49
Executive Function
Trails B 0.53 <0.001 0.52
Stroop Color/Word −0.51 <0.001 0.32
COWAT −0.27 <0.001 0.11
Attention
Trails A 0.52 <0.001 0.41
Digit Span Forward −0.21 <0.001 0.06
Digit Span Backward −0.37 <0.001 0.18
Language
BNT −0.44 <0.001 0.14
Animal Fluency −0.56 <0.001 0.41
Visuospatial
Block Design −0.24 0.08 –
JLO −0.28 <0.001 0.11
R2 value derived from least median of squares regression model; R2 for Block Design could not be derived to a large number of missing AD
cases.
moderate correlation with the MoCA (r = −0.68) and a
weak correlation with Clock Draw (r = −0.32). The AQ
alsodemonstratedmoderatecorrelationswithmeasures
of memory and executive function, as lower perfor-
mance on the memory measures was associated with
greater reported impairment on the AQ. For the mea-
sures of attention, the AQ correlated moderately with
Trails-A,butdemonstratedweakcorrelationswithDigit
SpanForwardandDigitSpanBackward.Both language
measures also correlated moderately with the AQ. For
visuospatial function, the JLO demonstrated a weak
correlation with the AQ while Block Design demon-
strated no correlation as the correlation value was not
statistically significant. Measures of general cognition,
memory, and executive function each accounted for
a substantial proportion of variance in the AQ score.
Within-group correlations are shown in Table 3.
Analyses showing the added diagnostic value of the
AQ with select cognitive tests are shown in Table 4.
For these analyses, we selected measures of general
cognition delayed recall memory measures as they
are often used independently to differentiate clini-
cal groups while many of the other domain-specific
cognitive tests are often used in a broader diagnostic
framework and interpreted in relation to other tests. We
chose to limit our analyses to CN versus aMCI cases
as they would provide the most informative classifi-
cation data given that aMCI/AD research has shifted
toward identifying individuals in the pre-clinical stages
of the disease. On its own, the AQ demonstrated good
diagnostic accuracy for aMCI (AUC = 0.83, 95% CI:
(0.77, 0.88)). When used in combination with different
cognitive tests, the only test which showed significant
benefit of the AQ’s addition was the MMSE as the AUC
value significantly improved.
The association statistics for the GDS as it was used
in the logistic regression models are shown in Table 5.
For all of the models, no significant association was
present.
DISCUSSION
The results of this study demonstrate that the AQ,
an informant-based assessment, correlates well with
several performance-based neuropsychological and
cognitive screening tests commonly used in clinical
settings. The AQ correlates most strongly with the
DRS-2, MMSE, and the MoCA. In the current study,
the AQ demonstrated stronger correlations with the
MoCA and MMSE than those reported previously
(MMSE, r = −0.56; MoCA, r = −0.46) [8], possibly
due to the larger sample size of the current study.
The use of a larger sample size allows for more a
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Table 3
Within-group correlation values for neuropsychological tests with the AQ
Domain Test CN aMCI AD
General Cognition
MMSE 0.15 −0.82 −0.34
MoCA −0.28 0.37 −0.12
DRS-2 −0.31 −0.26 −0.61
Clock Draw 0.29 0.30 −0.37
Memory
AVLT Total −0.22 0.12 −0.03
AVLT Delayed Recall −0.04 0.46 −0.02
BVMT-R Total −0.48 −0.17 −0.34
BVMT-R Delayed Recall −0.60 0.31 −0.05
Executive Function
Trails B 0.09 −0.29 0.41
Stroop Color/Word −0.34 −0.55 −0.31
COWAT −0.39 0.20 0.03
Attention
Trails A −0.01 0.35 0.23
Digit Span Forward 0.03 −0.19 −0.36
Digit Span Backward −0.13 0.06 −0.30
Language
BNT 0.10 0.20 −0.30
Animal Fluency −0.25 −0.23 0.09
Visuospatial
Block Design 0.05 −0.20 ***
JLO 0.04 −0.06 −0.20
Table 4
Additional diagnostic accuracy of select cognitive tests with AQ in aMCI cases
Test only Test with AQ p-value
AQ AUC = 0.83 95% CI: (0.77, 0.88) na na
DRS-2 Total AUC = 0.90 95% CI: (0.80, 0.96) AUC = 0.94 95% CI: (0.86, 0.99) 0.46
MMSE AUC = 0.79 95% CI: (0.73, 0.85) AUC = 0.88 95% CI: (0.83, 0.92) 0.02
MoCA AUC = 0.87 95% CI: (0.80, 0.92) AUC = 0.90 95% CI: (0.85, 0.95) 0.43
AVLT Delayed Recall AUC = 0.94 95% CI: (0.90, 0.97) AUC = 0.97 95% CI: (0.94, 0.99) 0.13
BVMT-R Delayed Recall AUC = 0.87 95% CI: (0.82, 0.91) AUC = 0.91 95% CI: (0.86, 0.94) 0.21
AUC, Area Under the Curve; 95% CI, 95% Confidence Interval; AQ, Alzheimer’s Questionnaire; DRS-2, Dementia Rating Scale; MMSE,
Mini-Mental State Exam; MoCA, Montreal Cognitive Assessment; AVLT, Auditory Verbal Learning Test; BVMT-R, Brief Visuospatial Memory
Test.
performance-based neuropsychological and screening
tests which strengthens its validity as an informant-
based assessment that can be applied and utilized in
clinical settings.
Other studies investigating the correlation between
informant-based screening measures and objective
cognitive tests have found that the AD8 is moder-
ately correlated with the MMSE (r = −0.41, r = −0.64)
[4, 26], while the reported correlation values for the
IQCODE and MMSE have varied widely (r = −0.37
to r = −0.78) [5]. Galvin et al. [4] reported that
the AD8 demonstrated weak correlations with neu-
ropsychological tests of specific domains such as
memory (WMS Logical Memory, r = −0.38 and 10-
Item Word List, r = −0.39) and language (Animal
Fluency, r = −0.05 and BNT, r = −0.02); however,
executive function measures (Trails-B, r = 0.47 and
Digit Symbol, r = −0.52) demonstrated moderate cor-
relations with the AD8. Jorm [5] reported on the
findings of several studies showing weak correlations
between the IQCODE and several neuropsychological
measures (WMS Logical Memory, r = −0.42; AVLT,
r = −0.35; Block Design, r = −0.28; and Digit Span,
r = −0.27).
Like the AD8 and IQCODE, the AQ demonstrated
some weak correlations with several neuropsycholog-
ical tests examining specific domains; however, several
moderatecorrelationswerealsonoted,particularlywith
measures of memory and executive function. Given that
decreased memory and dual processing skills are hall-
markfeatures thatdirectacliniciantoadiagnosisofAD,
these results suggest that the AQ is accurately assess-
ing AD-specific cognitive declines. Weak correlations
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Table 5
Association statistics for the GDS covariate in the diagnostic accuracy models
Test only Test with AQ
AQ OR = 1.01 na
95% CI: (0.94, 1.09)
p = 0.77
DRS-2 Total OR = 1.08 OR = 1.06
95% CI: (0.86, 1.37) 95% CI: (0.82, 1.38)
p = 0.49 p = 0.65
MMSE OR = 1.05 OR = 1.01
95% CI: (0.98, 1.11) 95% CI: (0.93, 1.09)
p = 0.17 p = 0.83
MoCA OR = 1.00 OR = 0.99
95% CI: (0.92, 1.08) 95% CI: (0.90, 1.09)
p = 0.98 p = 0.79
AVLT Delayed Recall OR = 0.98 OR = 0.93
95% CI: (0.90, 1.06) 95% CI: (0.84, 1.02)
p = 0.61 p = 0.13
BVMT-R Delayed Recall OR = 1.05 OR = 1.02
95% CI: (0.98, 1.13) 95% CI: (0.94, 1.11)
p = 0.14 p = 0.59
OR, Odds Ratio; 95% CI, 95% Confidence Interval; p, p-value; AQ, Alzheimer’s Questionnaire; DRS-2,
Dementia Rating Scale; MMSE, Mini-Mental State Exam; MoCA, Montreal Cognitive Assessment; AVLT,
Auditory Verbal Learning Test; BVMT-R, Brief Visuospatial Memory Test.
specific neuropsychological tests may be expected
to some extent given that informant-based measures
oftencontainitemsspanningseveralcognitivedomains.
Thus, the lack of overlap in the constructs measured by
broad informant-based and domain-specific neuropsy-
chological measures may explain weak correlations
between these assessment types. Additionally, as some
of these domains, such as visuospatial, are not typi-
cally expected to have significant involvement in AD,
one would expect the AQ to have lower correlations
withthesedomainsthanthedomainswithdeclinesmore
strongly associated with AD, such as memory and exec-
utive function.
There was considerable heterogeneity in the amount
of variance accounted for in each neuropsychologi-
cal test by the AQ as it accounted for most variability
in the memory and executive function domains. Even
with a relatively large amount of variance accounted for
in these domains, a fair amount of variance remained
unaccounted for. Since the AQ is an informant-based
screening measure, it is inevitable that other sources of
variability that underlie cognitive impairment, such as
age and education, will not be captured. Within the con-
text of screening one would not expect the AQ to fully
predict impairment in specific domains nor would it be
expected that the AQ be completely concordant with
a specific diagnosis. The weak and moderate corre-
lations with domain-specific neuropsychological tests
may also be due to structure of the measure, as some
AQ domains contain more items than others and are
thus represented more heavily than others within the
AQ total score. The AQ contains several items relat-
ing to memory, orientation, and functional ability, but
only a few items relating to language and visuospatial
domains. This might explain the moderate correlations
found for the neuropsychological tests of memory and
executive function and the weak correlations with visu-
ospatial tests. However, the imbalance of items within
the AQ is due to its initial conceptualization as an instru-
ment designed to detect symptoms associated with
aMCI and AD [6, 7], which tend to be concentrated in
the areas of memory and executive function.
Another important consideration is that the AQ relies
heavily on reported functional status in activities of
daily life. Difficulties noted by family members may
not emerge on neuropsychological instruments admin-
istered in a more controlled testing environment, which
may impact the strength of the correlations between the
AQ and neuropsychological measures. However, the
moderate and strong correlations in this study provide
evidence that informant-reported symptoms on the AQ
correspond well to the results of performance-based
cognitive assessments. It is interesting to note that
the AQ did not significantly improve diagnostic accu-
racy when combined with other cognitive tests. The
exception to this was the MMSE where the AUC value
improved significantly when the AQ was added to the
prediction model. Given that the MMSE is still one of
the most widely-used cognitive screening instruments,
using the AQ in conjunction with the MMSE may help-
ful in accurately identifying aMCI cases. Although
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the diagnostic accuracy of the other instruments, hav-
ing information from the AQ may be helpful in cases
where individuals are demonstrating impairment in
daily function but are performing within normal limits
on cognitive tests [27]. Rizk-Jackson et al. [28] found
that functional decline among cognitively normal indi-
viduals may precede cognitive decline in the process of
converting to aMCI. Juva and Sulkava [29] reported a
case-study in which an individual demonstrated sig-
nificant functional impairment, but whose cognitive
testing was within normal limits. They also note that
cognitive screening measures may be insensitive cog-
nitive changes in atypical presentations of AD and that
these measures may not be able to detect impairment
in individuals with high levels of education.
While the large sample size was able to add strength
to the correlations, one weakness of the study is the
ethnically homogenous sample with a majority of par-
ticipants in the study identifying as white. It is therefore
unclear if these results are generalizable to more ethni-
cally diverse populations. Another potential limitation
lies in the cross-sectional design of the study as it
is unclear whether longitudinal changes in the AQ
correspond with longitudinal changes in the neuropsy-
chological tests.
The results of this study provide further evidence
to support the validity of the AQ as an instrument for
detecting cognitive impairment associated with aMCI
and AD. In particular, the AQ demonstrated moderate
correlations with memory and executive function mea-
sures which shows that the AQ can reasonably assess
cognitive impairment demonstrated on standard neu-
ropsychological measures. Given the AQ’s ease of use
and short duration of administration, the results of this
study also demonstrate that it could provide a great
deal of value to general and geriatric practitioners who
desire a screening instrument that is highly predictive
of aMCI and AD.
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Abstract
Introduction: Longitudinal assessment of cognitive decline in amnestic mild cognitive impairment (aMCI) and
Alzheimer’s disease (AD) often involves the use of both informant-based and objective cognitive assessments. As
efforts have focused on identifying individuals in pre-clinical stages, instruments that are sensitive to subtle cognitive
changes are needed. The Alzheimer’s Questionnaire (AQ) has demonstrated high sensitivity and specificity in identifying
aMCI and AD; however its ability to measure longitudinal change has not been assessed. The aims of this study are to
assess the sensitivity to change of the AQ and to determine whether the AQ predicts change in global cognition and
function in cognitively normal (CN), aMCI, and AD subjects.
Methods: Data from 202 individuals participating in a brain and body donation program were utilized for this study
(101 CN, 62 aMCI, 39 AD). AD and aMCI individuals were matched on age, education, and gender to CN individuals.
Sensitivity to change of the AQ was assessed in addition to the AQ’s ability to predict change in global cognition and
function. The Mini Mental State Exam (MMSE) and Functional Activities Questionnaire (FAQ) were used as gold
standard comparisons of cognition and function. Sample size calculations for a 25% treatment effect were also
carried out for all three groups.
Results: The AQ demonstrated small sensitivity to change in the aMCI and CN groups (d = 0.33, d = 0.23, respectively)
and moderate sensitivity to change in the AD group (d = 0.43). The AQ was associated with increases in the Clinical
Dementia Rating Global Score (OR = 1.20 (1.09, 1.32), P <0.001). Sample size calculations found that the AQ would require
substantially fewer subjects than the MMSE given a 25% treatment effect.
Conclusions: Although the AQ demonstrated small sensitivity to change in aMCI and CN individuals in terms of effect
size, the AQ may be superior to objective cognitive tests in terms of required sample size for a clinical trial. As clinicians
and researchers continue to identify and treat individuals in earlier stages of AD, there is a need for instruments that are
sensitive to cognitive changes in these earlier stages.
Introduction
Longitudinal assessment of cognitive decline in amnestic
mild cognitive impairment (aMCI) and Alzheimer’s
disease (AD) often involves the use of both informant-
based and patient-based assessments to measure the
degree of change in cognition and function [1,2]. In both
clinical and research settings, the two methods are often
used in conjunction in order to glean a more accurate
picture of an individual’s current cognitive status relative
to baseline or other prior time points. A major issue that
both clinicians and researchers grapple with is the
degree to which a particular instrument is sensitive to
change over time. For clinicians, determining the signifi-
cance of change from one time to the next has implica-
tions for decisions regarding treatment and resource use
(that is, assisted living, in-home care, and so on.). Clini-
cians may also benefit from instruments that are sensitive
to change over time in order to satisfy the Affordable
Care Act’s cognitive screening requirement for Medicare
recipients. For researchers and clinical trialists, the issue
of sensitivity to change for a particular instrument has
significant ramifications for whether or not a meaningful
treatment effect will be detected between placebo and
treatment groups.
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The need to identify individuals as early as possible in
the AD disease process has prompted researchers to
begin conducting studies with individuals who are classi-
fied as having pre-symptomatic AD. Although no formal
diagnostic criteria currently exist for this classification, it
is used to classify individuals whose biological markers
are consistent with the pathological presence of AD, but
who are cognitively normal and are considered to be at
risk for eventually developing clinical AD. An interesting
study by Riley et al. [3] compared cognitively normal
individuals who, at autopsy, met National Institute on
Aging (NIA)-Reagan criteria for no- and low-likelihood
of AD with cognitively normal individuals who met cri-
teria for intermediate- and high-likelihood of AD. This
study found that the intermediate- and high-likelihood
groups had a steeper rate of decline on several cognitive
measures across several domains, although all individ-
uals in the study were within normal limits on cognitive
testing. Riley et al. [3] suggest that rates of longitudinal
cognitive decline may be informative in identifying indi-
viduals with pre-symptomatic AD, even when cognitive
testing falls within normal limits. Gavett et al. [4] found
that informant-reported cognitive symptoms on the
Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE) correlated well with longitudinal neuro-
psychological performance and that informant-reported
changes in cognition were a robust predictor of cognitive
decline in a high-functioning, cognitively normal group.
Both of these studies demonstrate that cognitive decline
in cognitively normal individuals can be reliably detected
and may be used to predict subsequent development of
clinical AD.
The Alzheimer’s Questionnaire (AQ) was originally in-
troduced in 2010 [5] and has been validated as an accur-
ate informant-based measure of cognition and function
for both aMCI and AD [5-7]. The AQ also correlates
well with established measures of cognition and global
function [8]. Although the AQ has demonstrated its
validity in cross-sectional studies, its ability to accurately
measure change in cognition over time has not been
assessed. Instruments such as the Mini Mental State Exam
(MMSE) [9] and the Functional Activities Questionnaire
(FAQ) [10] are commonly used to assess changes in cogni-
tion and function in aMCI and AD. Clark et al. [11] report
that although the MMSE may be sufficient to use as a
screening instrument for cognitive impairment, its utility
as an instrument to assess change over time accurately is
limited by high measurement error and high variability
of annual change between individuals. A recent study
by Costa et al. [12] found that the Montreal Cognitive
Assessment (MoCA) yielded small sensitivity to change
in prodromal AD and moderate sensitivity to change in
mild AD. Recent studies suggest that the FAQ is a sig-
nificant predictor of conversion to AD from aMCI [13]
and has also been associated with longitudinal decreases
in glucose metabolism associated with aMCI and AD
[14]. Rizk-Jackson et al. [15] found that the FAQ was able
to detect functional decline in cognitively normal individ-
uals prior to the presence of impairment on objective
cognitive tests.
The first aim of this study was to assess the sensitivity
to change of the AQ through the use of effect size and
sample size calculations for a hypothetical placebo-
controlled clinical trial. For comparison, the MMSE and
FAQ were also used in order to gauge the AQ’s perform-
ance against instruments that have been more widely
used. The second aim of the study was to determine
how well one-year change in AQ total score predicts
global change as measured by the Functional Assessment
Staging Test (FAST) [16], Global Deterioration Scale




Data from the two most recent annual visits for 202
individuals participating in a brain and body donation
program [19] were utilized for this study. Participants
in this program were recruited predominantly from the
northwest region of the Phoenix, Arizona metropolitan
area. Approval for the brain and body donation pro-
gram was granted by the Banner Health Institutional
Review Board and informed consent was obtained from
all individuals prior to enrolling in the program. The
sample for this study ranged in age from 57 to 97 years
with a mean of 81.70 ± 7.25 and had a mean education
level of 14.74 ± 2.54 years and included 95 women and
107 men.
Of the 202 individuals, 101 were classified as cogni-
tively normal (CN), 62 were classified as amnestic mild
cognitive impairment (aMCI), and 39 were classified as
Alzheimer’s disease (AD) at the first visit. Each aMCI
and AD individual was matched on age, education,
and gender to a CN individual, without replacement.
When an exact match could not be found, a tolerance
of ± 2 years was used for age and education in order to
obtain an appropriate match. Both single and multiple
domain aMCI cases were categorized as aMCI and both
possible and probable AD were categorized as AD. The
AD cases met National Institute of Neurological and
Communicable Disorders and Stroke – Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) criteria [20] for a clinical diagnosis of probable or
possible Alzheimer’s disease. aMCI cases were diagnosed
as such based on Petersen criteria [21]. The CN cases were
defined as having no limitations of activities of daily living
by informant report and were within normal limits on
neuropsychological testing.
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Consensus diagnosis with a neurologist, geriatric psych-
iatrist and neuropsychologist was used to determine the
clinical status of each individual. Consensus diagnoses were
made based on neuropsychological testing results, neuro-
logical and physical exam, and interviews with an inform-
ant that assessed global cognitive status, functional status,
and mood and behavioral status.
Instruments
AQ [5,6] – A 21-item, informant-based dementia assess-
ment designed for ease of use in a primary care setting.
AQ items are divided into five domains including Memory,
Orientation, Functional Ability, Visuospatial Ability, and
Language. Items are posed in a yes/no format with the
sum of ‘yes’ items equaling the total AQ score (0-27).
Six items known to be predictive of a clinical AD diagnosis
are weighted more heavily in the total score by each being
worth two points rather than one.
FAQ [11] – An informant-based measure of instru-
mental activities of daily living (IADLs) which scores 10
items on a 0 to 3 scale, with higher scores corresponding
to greater impairment.
MMSE [9] – A brief, 30-item cognitive screening
instrument that includes items on Orientation, Memory,
Attention, Language and Visuospatial functions.
FAST [16] – A dementia staging instrument that classi-
fies individuals as Normal Aging, Possible Mild Cognitive
Impairment, Mild Cognitive Impairment, Mild Dementia,
Moderate Dementia, Moderately Severe Dementia and
Severe Dementia using a 1 to 7 scale where higher ratings
indicate greater severity.
GDS [17] – A dementia staging instrument divided
into seven different stages with increasing impairment
corresponding with higher stages (No Cognitive Decline,
Age-Associated Memory Impairment, Mild Cognitive
Impairment, Mild Dementia, Moderate Dementia, Moder-
ately Severe Dementia, Severe Dementia).
CDR [18] –A semi-structured, informant-based clinical
staging instrument that characterizes six domains of cogni-
tive and functional performance: Memory, Orientation,
Judgment and Problem Solving, Community Affairs, Home
and Hobbies, and Personal Care. The CDR provides a glo-
bal score which is a composite score based on an algorithm
that gives different weights to the scores for each of the do-
mains. The global score (GS) is used to grade the severity
of dementia and is measured using 0, 0.5, 1, 2, and 3 to de-
note no impairment, very mild dementia, mild dementia,
moderate dementia, and severe dementia, respectively.
Statistical analysis
The Shapiro-Wilk test was performed on the data to de-
termine the normality of distribution for the continuous
variables. Non-parametric tests for group comparisons
and correlations were used, as the data for all continuous
variables were not normally distributed. The Kruskall-
Wallis test was used to verify that the three groups were
not significantly different in terms of age and education.
Chi-square analysis was used to examine the distribution
of men and women among the three groups.
The analyses investigating the sensitivity to change uti-
lized a method similar to that of Costa et al. [11]. Mid-
del and von Sonderen [22,23] described these methods
and their rationale in detail. The sensitivity to change
assessment was completed through the calculation of an
effect size (ES) to quantify the magnitude of change.
Since this study used a correlated design, the pooled
standard deviation was used to calculate the ES which
was taken from the individual standard deviation values
for Year 1 and Year 2 for each measure (pooled standard
deviation = √(((Year 1 sd)2 + (Year 2 sd)2)/2); (ES =mean
change score/pooled standard deviation)). The final ef-
fect size measure, d, included a correction for reliability
(d = ES/√2(1-r)) where r is the correlation between
the scores at Year 1 and Year 2. The interpretation
for d utilized the following scheme proposed by Cohen
[24]: <0.20 = trivial change; 0.20 to 0.50 = small change;
0.50 to 0.80 =moderate change; ≥0.80 = large change.
In order to provide a more practical interpretation of
the sensitivity to change, a series of sample size calcula-
tions were carried out to show how many individuals
would be needed for a clinical trial using a particular
measure as its outcome. The sample size calculations as-
sumed a 25% treatment effect on the mean change score
for each measure at 80% power with a two-tailed signifi-
cance level of 0.05 for a randomized clinical trial with a
treatment arm and a placebo arm. These parameters
were used as they have been utilized by several previous
studies [25] and have also been used to estimate sample
sizes for pre-dementia trials using data from the Alzhei-
mer’s Disease Neuroimaging Initiative [26]. Sample size
calculations were carried out using G*Power 3 [27]. The
reported sample sizes are the number per arm. For each
of the clinical groups, varying trial lengths were used in the
sample size calculations: AD = two years, MCI = three
years, CN = five years.
To further examine the ability of each instrument to
detect clinically significant change, a reliable change
index (RCI) was calculated for each instrument. For this
study, two different RCI methods were utilized as the
AQ and FAQ are informant-based assessments and the
MMSE is an objective performance-based assessment.
For the AQ and FAQ, RCI calculations that corrected
for inter-test reliability were used [28] while the MMSE
RCI calculation utilized a method that corrects for both
inter-test reliability and practice effects [29]. The most
common convention for interpreting RCI scores is that
scores that are ≥ ± 1.645 are interpreted as demonstrat-
ing clinically significant change [30]. This was used to
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obtain 90% confidence intervals for estimates of clinic-
ally significant change for each instrument from Year 1
to Year 2. In this study, we report the percent of
individuals who demonstrated annual score changes
outside the range of the 90% confidence interval for each
instrument.
An additional set of analyses were carried out to deter-
mine the extent to which the mean change scores of the
AQ, FAQ and MMSE predicted global change as mea-
sured by increases in FAST, GDS and CDR-GS values.
The CN, AD and aMCI groups were analyzed separately.
An analysis with the entire sample was also carried out.
All individuals were dichotomized based on whether
their individual FAST, GDS and CDR-GS values in-
creased from Year 1 to Year 2 (1 = increase, 0 = no
increase) as increases on these scales represent clinically
meaningful changes in disease severity. Logistic regres-
sion analyses were used to assess the predictive value of
the AQ, FAQ and MMSE change scores on increases in
FAST, GDS or CDR-GS. A False Discovery Rate (FDR)
significance level of 0.006 was used to correct for
multiple comparisons within each of the groups.
Spearman correlation analyses were carried out to
assess the linear associations between AQ, FAQ and
MMSE scores with the FAST, GDS and CDR-GS for
Year 1 and Year 2 separately. Spearman correlation was
also used to assess the associations between the change
scores on the AQ, FAQ, MMSE and MoCA. The corre-
lations used as the measures of test-retest reliability are
also Spearman values. Statistical analyses were carried
out using Systat 12.0 (Systat, Inc., San Jose, CA, USA).
Results
Demographic characteristics of the entire study sample
and each clinical group are shown in Table 1. The three
clinical groups did not differ in terms of age or years of
education and there was no significant difference in gen-
der composition among the three groups.
The results from the sensitivity to change analysis are
shown in Table 2. In the aMCI group the AQ, FAQ and
MMSE all demonstrated small sensitivity to change in
terms of their respective d values (0.33, 0.35, 0.24). How-
ever, both the AQ and FAQ yielded required sample
sizes that were less than half of the sample size required
by the MMSE.
In the AD group, the AQ demonstrated small sensitiv-
ity to change (d = 0.43),; however, the FAQ showed large
sensitivity to change (d = 0.84) and the MMSE demon-
strated moderate sensitivity to change (d = 0.52). In
terms of required sample size the FAQ yielded the
lowest value (n = 119) while the AQ yielded a value that
was substantially higher (n = 232). This result may be ex-
plained by the reliability values for each instrument as
the FAQ had a higher reliability value (r = 0.81) than the
AQ (r = 0.64). The MMSE yielded a required sample size
that was between that of the AQ and FAQ (n = 157).
In the CN group all three measures demonstrated trivial
sensitivity to change. However, sample size calculations
demonstrated that the MMSE would require substantially
more subjects than both the AQ and FAQ.
Results from the RCI score calculations are shown in
Table 3. For the aMCI group, the AQ yielded a higher
percentage of individuals demonstrating clinically signifi-
cant change when compared to the FAQ and MMSE.
For the AD group, the AQ yielded a higher percentage
of individuals demonstrating clinically significant change
when compared to the FAQ, but demonstrated an
equivalent percentage compared to the MMSE. Table 4
shows the results of the predictive ability of AQ, FAQ
and MMSE mean change scores on increases in FAST,
GDS and CDR-GS values. Within each of the clinical
groups, no statistically significant effects were found after
adjusting for multiple comparisons. When all three
groups were pooled together, the AQ and FAQ dem-
onstrated small, but significant associations with CDR-
GS increases (AQ (odds ratio (OR) = 1.20 (1.09, 1.32),
P <0.001); FAQ (OR = 1.21 (1.11, 1.33), P <0.001)). The
pooled analysis also yielded a small, but significant associ-
ation for FAQ mean change and GDS increase (OR = 1.16
(1.06, 1.26), P = 0.001).
Correlation values for first and second year scores for
each instrument are shown in Tables 5 and 6. The AQ
and FAQ correlated strongly with FAST, GDS and CDR-
GS values in both years while the MMSE correlated
moderately with FAST, GDS and CDR-GS values in Year
1. In Year 2, the MMSE correlated moderately with the
FAST and GDS, but demonstrated a strong correlation
with the CDR-GS.
The mean change score for the AQ correlated weakly
with the mean FAQ change score (r = 0.22, P = 0.002)
Table 1 Demographic characteristics
Characteristic CN MCI AD Total P-value
Number 101 62 39 202 -----
Age 81.76 ± 7.23 81.57 ± 7.59 81.82 ± 6.92 81.71 ± 7.25 0.99
Education 14.69 ± 2.50 15.18 ± 2.56 14.15 ± 2.55 14.74 ± 2.54 0.12
Gender (M/F) 53/48 33/29 21/18 107/95 0.99
Mean ± standard deviation. AD, Alzheimer’s disease; CN, cognitively normal; MCI, mild cognitive impairment; M/F, male/female.
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while the MMSE mean change score demonstrated no
correlation with the AQ mean change score (r = -0.02,
P = 0.83).
Discussion
Within the aMCI and AD groups the AQ demonstrated
small sensitivity to change while its sensitivity to change
in the CN group was trivial. In aMCI individuals the
AQ, FAQ and MMSE all demonstrated small sensitivity
to change. In the AD group, the MMSE and FAQ dem-
onstrated greater sensitivity to change relative to the
AQ. The AQ was also significantly associated with global
change as measured by CDR-GS increase and correlated
strongly with other established measures of global cogni-
tion and function. Although the effect sizes reported in
this study are relatively small, they are consistent with
the notion that cognitive changes associated with aMCI
and AD are often subtle and difficult to detect from a
psychometric standpoint. This point is a major challenge
for researchers and clinical trialists as the variability of
cognitive tests is often numerically similar to the rate of
change [31]. Informant-based instruments that assess
functional ability are also prone to high degrees of vari-
ability due to varying pre-morbid levels of function and
gender differences in the degree of participation in many
of the functional activities that are assessed [31]. The re-
sult is that when objective cognitive tests and informant-
based instruments are used as endpoints in clinical trials
the inherent variability of these measures often makes it
difficult to detect true differences between placebo and
treatment groups. However, others have suggested that
lack of decline in placebo groups [32] and disease sever-
ity at baseline [31] can also significantly impact a trial’s
ability to detect a significant treatment effect. The degree
to which a particular cognitive or functional measure is re-
sponsive to changes in disease status is extremely import-
ant, particularly in pre-symptomatic and aMCI populations
where cognitive decline is slower and more subtle [33].
The sample size calculations in the aMCI group dem-
onstrate that the AQ is superior to the MMSE in terms
of sensitivity to change; however, the AQ required a larger
sample size than the FAQ. The sample size calculations
Table 2 Sensitivity to change comparison for the AQ, FAQ, and MMSE in amnestic mild cognitive impairment,
Alzheimer’s disease, and cognitively normal cases
Group Instrument Mean change SD of mean change 95% CI of mean change Pooled SD ES Reliability d Required sample
sizea
aMCI
AQ 1.66 4.96 (0.40, 2.92) 6.10 0.27 0.65 0.33 251
FAQ 2.05 5.79 (0.54, 3.56) 3.29 0.30 0.63 0.35 224
MMSE -0.55 2.54 (-1.19, 0.10) 2.47 0.22 0.56 0.24 597
AD
AQ 2.49 4.77 (0.94, 4.03) 6.75 0.37 0.64 0.43 232
FAQ 3.59 4.91 (2.00, 5.18) 5.36 0.52 0.81 0.84 119
MMSE -2.13 3.35 (-3.23, -1.03) 6.34 0.34 0.79 0.52 157
CN
AQ 0.47 2.73 (-0.07, 1.00) 3.37 0.14 0.69 0.18 340
FAQ 0.33 1.80 (-0.03, 0.69) 3.29 0.11 0.73 0.15 300
MMSE 0.05 1.71 (-0.29, 0.39) 2.47 0.02 0.41 0.02 660
aNumber of subjects per arm based on a 25% treatment effect of the mean change at 80% power with a two-tailed significance level of 0.05; sample size estimates are
based on a two-year study for AD, a three-year study for aMCI, and five-year study for CN; for AQ and FAQ positive mean change scores represent increased impairment
over time and negative mean change scores for MMSE also represent increased impairment over time. Effect size values are reported in absolute values and represent
the magnitude of the difference for Year 2 scores subtracted from Year 1 scores. AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AQ, Alzheimer’s
Questionnaire; 95% CI, 95% confidence interval; CN, cognitively normal; d, effect size corrected for reliability; ES; effect size using pooled standard deviation;
FAQ, Functional Activities Questionnaire; MMSE, Mini Mental State Exam; SD, standard deviation.
Table 3 Reliable change index results based on data from cognitively normal individuals
Instrument Reliability SEm SEdiff 90% CI for RCI Percent outside of 90% CI
AQ 0.69 0.27 2.66 ±4.37 aMCI = 24%; AD = 16%
FAQ 0.73 0.18 2.24 ±3.67 aMCI = 17%; AD = 12%
MMSE 0.41 0.17 1.73 ±2.84 aMCI = 17%; AD = 17%
AD, Alzheimer’s disease; AQ, Alzheimer’s Questionnaire; CI, confidence interval; FAQ, Functional Activities Questionnaire; MMSE, Mimi Mental State Exam; RCI,
reliable change index; SEdiff, standard error of the difference; SEm, standard error of measurement.
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highlight some important methodological issues in aMCI
and AD studies that have been problematic. The first issue
involves whether or not objective cognitive tests and
informant-based instruments are sensitive enough to
detect changes, particularly in earlier stages of aMCI and
AD. Based on the results from the MMSE, our results sug-
gest that the AQ may be superior to objective cognitive
measures in detecting longitudinal change when com-
pared on sample sizes required to detect a treatment
effect. Although informant-based and objective cogni-
tive assessments are often used in conjunction to as-
sess drug efficacy, these results suggest that the MMSE is
less sensitive to change over time than informant-based
instruments.
Another issue these results highlight is that of instru-
ment reliability as it relates to the required sample size
needed to detect a treatment effect. There is a direct re-
lationship between instrument reliability and sensitivity
to change as instruments that are prone to higher vari-
ability between assessments may not detect significant
longitudinal change as accurately as instruments with
lower between-assessment variability. This imprecision
ultimately leads to larger sample size requirements for
clinical trials. Knopman and Caselli [34] point out that
between-assessment variability is an inherent challenge
when using patient-based objective cognitive tests to as-
sess change, and longitudinal differences may be related
to non-pathological factors, such as chance and regres-
sion toward the mean. Practice effects due to repeat
administration of cognitive tests within relatively short
periods of time also pose a significant threat to the
ability to detect change associated with progression of
Table 4 AQ, FAQ, and MMSE mean change as predictors of global change in mild cognitive impairment, Alzheimer’s
disease, cognitively normal cases, and all groups combined
Group Instrument FAST increase GDS increase CDR Global score increase
aMCI
AQ 1.07 (0.96, 1.20); P = 0.23 1.09 (0.97, 1.22); P = 0.15 1.09 (0.97, 1.24); P = 0.16
FAQ 1.07 (0.96, 1.19); P = 0.25 0.97 (0.87, 1.08); P = 0.52 1.08 (0.96, 1.22); P = 0.22
MMSE 1.02 (0.83, 1.26); P = 0.83 0.81 (0.64, 1.02); P = 0.07 0.91 (0.72, 1.15); P = 0.43
AD
AQ 1.17 (0.97, 1.29); P = 0.14 1.26 (1.05, 1.52); P = 0.01 1.16 (1.00, 1.35); P = 0.06
FAQ 1.09 (0.95, 1.24); P = 0.22 1.17 (1.00, 1.38); P = 0.05 1.12 (0.97, 1.29); P = 0.12
MMSE 0.93 (0.77, 1.14); P = 0.50 0.97 (0.79, 1.19); P = 0.77 0.91 (0.74, 1.11); P = 0.35
CN
AQ 1.09 (0.93, 1.28); P = 0.29 1.04 (0.88, 1.23); P = 0.67 1.26 (1.00, 1.59); P = 0.05
FAQ 0.91 (0.68, 1.22); P = 0.52 1.02 (0.77, 1.34); P = 0.92 1.61 (1.10, 2.36); P = 0.02
MMSE 0.88 (0.66, 1.17); P = 0.38 0.94 (0.70, 1.25); P = 0.66 0.72 (0.35, 1.49); P = 0.37
All Groups Combined
AQ 1.11 (1.03, 1.20); P = 0.008 1.08 (1.00, 1.16); P = 0.05 1.20 (1.09, 1.32); P <0.001
FAQ 1.09 (1.01, 1.18); P = 0.03 1.16 (1.06, 1.26); P = 0.001 1.21 (1.11, 1.33); P <0.001
MMSE 0.91 (0.81, 1.03); P = 0.15 0.84 (0.74, 0.95); P = 0.006 0.91 (0.74, 1.11); P = 0.35
Odds ratio (95% confidence interval); P-value; FDR significance level = 0.006; odds ratios indicate the association for a 1-point increase in AQ, FAQ, and MMSE
change scores with FAST, GDS and CDR-GS score increase as the outcome. AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AQ, Alzheimer’s
Questionnaire; CI, confidence interval; CDR, Clinical Dementia Rating; CN, cognitively normal; FAQ, Functional Activities Questionnaire; FAST, Functional Assessment
Staging Test; GDS, Global Deterioration Score; MMSE, Mini Mental State Exam; MoCA, Montreal Cognitive Assessment.
Table 5 Correlation values for AQ, FAQ, MMSE, FAST, GDS
and CDR Global Score for Year 1
Instrument FAST Year 1 GDS Year 1 CDR-GS Year 1
AQ Year 1 0.84 0.78 0.74
FAQ Year 1 0.83 0.77 0.75
MMSE Year 1 -0.59 -0.64 -0.65
P <0.001 for all correlations. AQ, Alzheimer’s Questionnaire; CDR, Clinical
Dementia Rating; FAQ, Functional Activities Questionnaire; FAST, Functional
Assessment Staging Test; GDS, Global Deterioration Scale; MMSE, Mini Mental
State Exam.
Table 6 Correlation values for AQ, FAQ, MMSE, FAST, GDS
and CDR Global Score for Year 2
Instrument FAST Year 2 GDS Year 2 CDR-GS Year 2
AQ Year 2 0.80 0.80 0.75
FAQ Year 2 0.81 0.81 0.83
MMSE Year 2 -0.67 -0.72 -0.69
P <0.001 for all correlations. AQ, Alzheimer’s Questionnaire; CDR, Clinical
Dementia Rating; FAQ, Functional Activities Questionnaire; FAST, Functional
Assessment Staging Test; GDS, Global Deterioration Scale; MMSE, Mini Mental
State Exam.
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aMCI/AD [35]. Others have also suggested that some
objective cognitive tests are inherently insensitive to cog-
nitive changes [36] and that variability between exam-
iners using these instruments [37] is also a detrimental
factor that prevents treatment effects from being ob-
served. Although informant-based measures are more
robust to some of these challenges than objective cogni-
tive tests, they are still prone to some degree of meas-
urement error, particularly in the area of inter-rater
reliability [38].
In this study, the issue of reliability and its relationship
to effect size was demonstrated in the AD group where
the AQ yielded moderate sensitivity to change and the
FAQ yielded large sensitivity to change. In this case, the
effect size (corrected for reliability) for the FAQ was
almost twice as large as that of the AQ. Some of this
difference may be attributable to the higher reliability
value of the FAQ which underscores the importance of
not only an instrument’s psychometric ability to detect
change, but also the ability of the examiner to admin-
ister the instrument in a way that can detect meaning-
ful change. The importance of inter-rater reliability is
highlighted by Kobak [39] who points out that reduc-
tions in inter-rater reliability, as measured by intra-class
correlation, can result in significantly larger required sam-
ple sizes for clinical trials which stems from the increased
measurement variability that reduces statistical power.
This issue is also highlighted by Cummings et al. [40] who
report that insufficient training and monitoring of exam-
iners may lead to increased measurement variability which
decreases the chance of detecting significant treatment
effects. Connor and Sabbagh [41] also note that increases
in measurement error may lead to decreases in instrument
reliability, which results in a decreased ability to detect
treatment effects.
The divergent sample size calculations for the AQ and
FAQ may also be due to some of the inherent psycho-
metric properties of each instrument. The FAQ captures
not only the presence of impaired functioning, but also
severity where the AQ only captures the presence of
reported impairment in cognition and function. Thus,
the inclusion of severity of impairment on the FAQ may
account for the smaller required sample size calculation
as a result of increased statistical power.
The results from the RCI calculations showed that the
AQ identified clinically significant change in a larger
percentage of individuals than did the FAQ and MMSE
for aMCI individuals. The advantage that RCI scores
provide is the ability to assess intra-individual change,
which has been shown to have good predictive value in
terms of cognitive decline [42]. The use of RCI scores in
this context may provide a novel and more informative
way to determine endpoints for aMCI and AD clinical
trials. Since the majority of clinical trials for aMCI and
AD rely on methods and analyses that simply assess
group differences (for example, drug versus placebo) on
a particular measure (for example, Alzheimer’s Disease
Assessment Scale – cognition (ADAS-Cog)), it might be
possible for drug efficacy to be assessed based on the per-
cent of individuals showing clinically significant change
on a measure, rather than just demonstrating a certain
amount of change (for example, 25%) on an outcome
measure.
One drawback to the current study is the relatively
small sample size. Given that clinical trials often enroll
hundreds of individuals, replication of these findings in a
larger sample is needed in order to strengthen the argu-
ment for the AQ’s ability to detect longitudinal change.
Autopsy confirmation of the clinical status for each indi-
vidual would lend further support to the AQ’s ability to
detect longitudinal change. Although the individuals par-
ticipating in this study have agreed to an autopsy, many
of them were still living at the time of the analysis so
neuropathological confirmation of their clinical status
was not available.
Conclusions
The results of this study indicate that the AQ demon-
strated small sensitivity to longitudinal cognitive changes
associated with aMCI and AD. The AQ’s sensitivity to
change in aMCI was comparable to the FAQ while both
instruments outperformed the MMSE in terms of effect
size and required sample size. The AQ was also signifi-
cantly associated with longitudinal decreases in global
cognition and function and was able to identify a greater
proportion of aMCI individuals with clinically significant
change when compared to other established measures.
As clinicians and researchers continue to identify and
treat individuals in earlier stages of AD, there is a need
to utilize instruments that are sensitive to subtle cogni-
tive changes over time. Although the AQ’s sensitivity
to change was small, it is possible that its sensitivity
to change may be enhanced when used in conjunction
with sensitive objective cognitive tests and validated bio-
markers of disease progression. In addition, the recent
changes in mandatory screening measures for Medicare
recipients as part of the Affordable Care Act may pro-
vide the opportunity for the AQ to be used by clinicians
in order to satisfy the requirement for cognitive screen-
ing and might be helpful in detecting change over time
in clinical settings.
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